

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau(43) International Publication Date  
18 November 2004 (18.11.2004)

PCT

(10) International Publication Number  
WO 2004/099247 A2(51) International Patent Classification<sup>7</sup>: C07K 14/70Via Pontina KM 30.600, I-00040 Pomezia, Rome (IT).  
MENNUNI, Carmela [IT/IT]; IRBM, Via Pontina KM  
30.600, I-00040 Pomezia, Rome (IT). SAVINO, Rocco  
[IT/IT]; IRBM, Via Pontina KM 30.600, I-00040 Pomezia,  
Rome (IT).(21) International Application Number:  
PCT/EP2004/004802

(22) International Filing Date: 3 May 2004 (03.05.2004)

(74) Agent: BUCHAN, Gavin, MacNicol; Terlings Park, East-  
wick Road, Harlow, Essex CM20 2QR (GB).

(25) Filing Language: English

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(26) Publication Language: English


(30) Priority Data:  
60/467,971 5 May 2003 (05.05.2003) US  
60/543,612 11 February 2004 (11.02.2004) US(71) Applicant (for all designated States except US): ISTI-  
TUTO DI RICERCHE DI BIOLOGIA MOLECO-  
LARE P ANGELETTI SPA [IT/IT]; Via Pontina KM  
30.600, I-00040 Pomezia, Rome (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LA MONICA,  
Nicola [IT/IT]; IRBM, Via Pontina KM 30.600, I-00040  
Pomezia, Rome (IT). LAHM, Armin [DE/IT]; IRBM,(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,

[Continued on next page]

(54) Title: SYNTHETIC GENE ENCODING HUMAN CARCINOEMBRYONIC ANTIGEN AND USES THEREOF



(57) Abstract: Synthetic polynucleotides encoding human carcinoembryonic antigen (CEA) are provided, the synthetic polynucleotides being codon-optimized for expression in a human cellular environment. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying codon-optimized human CEA and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

WO 2004/099247 A2



SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *without international search report and to be republished upon receipt of that report*

## TITLE OF THE INVENTION

## SYNTHETIC GENE ENCODING HUMAN CARCINOEMBRYONIC ANTIGEN AND USES THEREOF

## 5 FIELD OF THE INVENTION

The present invention relates generally to the therapy of cancer. More specifically, the present invention relates to synthetic polynucleotides encoding the human tumor associated polypeptide carcinoembryonic antigen, herein designated hCEAopt, wherein the polynucleotides are codon-optimized for expression in a human cellular environment. The present invention also provides recombinant vectors and hosts comprising said synthetic polynucleotides. This invention also relates to adenoviral vector and plasmid constructs carrying hCEAopt and to their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

## BACKGROUND OF THE INVENTION

15 The immunoglobulin superfamily (IgSF) consists of numerous genes that code for proteins with diverse functions, one of which is intercellular adhesion. IgSF proteins contain at least one Ig-related domain that is important for maintaining proper intermolecular binding interactions. Because such interactions are necessary to the diverse biological functions of the IgSF members, disruption or aberrant expression of many IgSF adhesion molecules has been correlated with many human diseases.

20 The carcinoembryonic antigen (CEA) belongs to a subfamily of the Ig superfamily consisting of cell surface glycoproteins. Members of the CEA subfamily are known as CEA-related cell adhesion molecules (CEACAMs). In recent scientific literature, the CEA gene has been renamed CEACAM5, although the nomenclature for the protein remains CEA. Functionally, CEACAMs have been shown to act as both homotypic and heterotypic intercellular adhesion molecules (Benchimol et al., 25 *Cell* 57: 327-334 (1989)). In addition to cell adhesion, CEA inhibits cell death resulting from detachment of cells from the extracellular matrix and can contribute to cellular transformation associated with certain proto-oncogenes such as *Bcl2* and *C-Myc* (see Berinstein, *J. Clin Oncol.* 20(8): 2197-2207 (2002)).

Normal expression of CEA has been detected during fetal development and in adult colonic mucosa. CEA overexpression was first detected in human colon tumors over thirty years ago (Gold and Freedman, *J. Exp. Med.* 121:439-462 (1965)) and has since been found in nearly all colorectal tumors. Additionally, CEA overexpression is detectable in a high percentage of adenocarcinomas of the pancreas, breast and lung. Because of the prevalence of CEA expression in these tumor types, CEA is widely used clinically in the management and prognosis of these cancers.

Sequences coding for human CEA have been cloned and characterized (U.S. Patent No. 30 5,274,087; U.S. Patent No 5,571,710; and U.S. Patent No 5,843,761. See also Beauchemin et al., *Mol.*

*Cell. Biol.* 7:3221-3230 (1987); Zimmerman et al., *Proc. Natl. Acad. Sci. USA* 84:920-924 (1987); Thompson et al. *Proc. Natl. Acad. Sci. USA* 84(9):2965-69 (1987)).

The correlation between CEA expression and metastatic growth has led to its identification as a target for molecular and immunological intervention for colorectal cancer treatment. One therapeutic approach targeting CEA is the use of anti-CEA antibodies (*see* Chester et al., *Cancer Chemother. Pharmacol.* 46 (Suppl): S8-S12 (2000)), while another is to activate the immune system to attack CEA-expressing tumors using CEA-based vaccines (for review, *see* Berinstein, *supra*).

The development and commercialization of many vaccines have been hindered by difficulties associated with obtaining high expression levels of exogenous genes in successfully transformed host organisms. Therefore, despite the identification of the wild-type nucleotide sequences encoding CEA proteins described above, it would be highly desirable to develop a readily renewable source of human CEA protein that utilizes CEA-encoding nucleotide sequences that are optimized for expression in the intended host cell, said source allowing for the development of a cancer vaccine which is efficacious and not hindered by self-tolerance.

#### SUMMARY OF THE INVENTION

The present invention relates to compositions and methods to elicit or enhance immunity to the protein products expressed by CEA genes, which have been associated with numerous adenocarcinomas, including colorectal carcinomas. Specifically, the present invention provides polynucleotides encoding human CEA protein, wherein said polynucleotides are codon-optimized for high level expression in a human cell. The present invention further provides adenoviral and plasmid-based vectors comprising the synthetic polynucleotides and discloses use of said vectors in immunogenic compositions and vaccines for the prevention and/or treatment of CEA-associated cancer.

The present invention also relates to synthetic nucleic acid molecules (polynucleotides) comprising a sequence of nucleotides that encode human carcinoembryonic antigen (hereinafter hCEA) as set forth in SEQ ID NO:2, wherein the synthetic nucleic acid molecules are codon-optimized for high-level expression in a human cell (hereinafter hCEAopt). The nucleic acid molecules disclosed herein may be transfected into a host cell of choice wherein the recombinant host cell provides a source for substantial levels of an expressed functional hCEA protein (SEQ ID NO:2).

The present invention further relates to a synthetic nucleic acid molecule which encodes mRNA that expresses a human CEA protein; this DNA molecule comprising the nucleotide sequence disclosed herein as SEQ ID NO:1. A preferred aspect of this portion of the present invention is disclosed in FIGURE 1, which shows a DNA molecule (SEQ ID NO:1) that encodes a hCEA protein (SEQ ID NO:2 or SEQ ID NO:16). The preferred nucleic acid molecule of the present invention is codon-optimized for high-level expression in a human cell.

Another preferred DNA molecule of the present invention comprises a sequence of nucleotides that encodes a human CEA that is deleted of its C-terminal anchoring domain (AD), which is located from about amino acid 679 to about amino acid 702 of the human full-length CEA (SEQ ID NO:2), wherein said sequence of nucleotides is codon-optimized for high level expression in a human cell. An exemplary DNA molecule encoding a CEA variant that is truncated of its anchoring domain is set forth in SEQ ID NO:15 (shown in FIGURE 10A). The corresponding amino acid sequence of hCEA- $\Delta$ AD is set forth in SEQ ID NO:16 (shown in FIGURE 10B).

The present invention also relates to recombinant vectors and recombinant host cells, both prokaryotic and eukaryotic, which contain the nucleic acid molecules disclosed throughout this specification.

The present invention further relates to a process for expressing a codon-optimized human CEA protein in a recombinant host cell, comprising: (a) introducing a vector comprising a nucleic acid molecule as set forth in SEQ ID NO:1 or SEQ ID NO:15 into a suitable host cell; and, (b) culturing the host cell under conditions which allow expression of said codon-optimized human protein.

Another aspect of this invention is a method of preventing or treating cancer comprising administering to a mammal a vaccine vector comprising a synthetic nucleic acid molecule, the synthetic nucleic acid molecule comprising a sequence of nucleotides that encodes a human carcinoembryonic antigen (hCEA) protein as set forth in SEQ ID NO:2 or SEQ ID NO:16, wherein the synthetic nucleic acid molecule is codon-optimized for high level expression in a human cell.

The present invention further relates to an adenovirus vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising: (a) a codon-optimized polynucleotide encoding a human CEA protein; and (b) a promoter operably linked to the polynucleotide.

The present invention also relates to a vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising: (a) a synthetic polynucleotide encoding a human CEA protein, wherein the synthetic polynucleotide is codon-optimized for optimal expression in a human cell; and (b) a promoter operably linked to the polynucleotide.

Another aspect of the present invention is a method of protecting or treating a mammal from cancer or treating a mammal suffering from CEA-associated cancer comprising: (a) introducing into the mammal a first vector comprising: i) a codon-optimized polynucleotide encoding a human CEA protein; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and (c) introducing into the mammal a second vector comprising: i) a codon-optimized polynucleotide encoding a human CEA protein; and ii) a promoter operably linked to the polynucleotide.

As used throughout the specification and in the appended claims, the singular forms "a," "an," and "the" include the plural reference unless the context clearly dictates otherwise.

As used throughout the specification and appended claims, the following definitions and abbreviations apply:

5           The term "promoter" refers to a recognition site on a DNA strand to which the RNA polymerase binds. The promoter forms an initiation complex with RNA polymerase to initiate and drive transcriptional activity. The complex can be modified by activating sequences termed "enhancers" or inhibiting sequences termed "silencers".

10           The term "cassette" refers to the sequence of the present invention that contains the nucleic acid sequence which is to be expressed. The cassette is similar in concept to a cassette tape; each cassette has its own sequence. Thus by interchanging the cassette, the vector will express a different sequence. Because of the restriction sites at the 5' and 3' ends, the cassette can be easily inserted, removed or replaced with another cassette.

15           The term "vector" refers to some means by which DNA fragments can be introduced into a host organism or host tissue. There are various types of vectors including plasmid, virus (including adenovirus), bacteriophages and cosmids.

          The term "first generation," as used in reference to adenoviral vectors, describes said adenoviral vectors that are replication-defective. First generation adenovirus vectors typically have a deleted or inactivated E1 gene region, and preferably have a deleted or inactivated E3 gene region.

20           The designation "pV1J/hCEAopt" refers to a plasmid construct disclosed herein comprising the human CMV immediate-early (IE) promoter with intron A, a full-length codon-optimized human CEA gene, bovine growth hormone-derived polyadenylation and transcriptional termination sequences, and a minimal pUC backbone (see EXAMPLE 2). The designation "pV1J/hCEA" refers to a construct as described above, except the construct comprises a wild-type human CEA gene instead of a  
25           codon-optimized human CEA gene.

          The designations "MRKAd5/hCEAopt" and "MRKAd5/hCEA" refer to two constructs, disclosed herein, which comprise an Ad5 adenoviral genome deleted of the E1 and E3 regions. In the "MRKAd5/hCEAopt" construct, the E1 region is replaced by a codon-optimized human CEA gene in an E1 parallel orientation under the control of a human CMV promoter without intron A, followed by a  
30           bovine growth hormone polyadenylation signal. The "MRKAd5/hCEA" construct is essentially as described above, except the E1 region of the Ad5 genome is replaced with a wild-type human CEA sequence (see EXAMPLE 2).

          The term "effective amount" means sufficient vaccine composition is introduced to produce the adequate levels of the polypeptide, so that an immune response results. One skilled in the art  
35           recognizes that this level may vary.

A "conservative amino acid substitution" refers to the replacement of one amino acid residue by another, chemically similar, amino acid residue. Examples of such conservative substitutions are: substitution of one hydrophobic residue (isoleucine, leucine, valine, or methionine) for another; substitution of one polar residue for another polar residue of the same charge (e.g., arginine for lysine; glutamic acid for aspartic acid).

"hCEA" and "hCEAopt" refer to a human carcinoembryonic antigen and a human codon-optimized carcinoembryonic antigen, respectively.

The term "hCEA- $\Delta$ AD" refers to a variant of human CEA that is deleted of its C-terminal anchoring domain (AD), which is located from about amino acid 679 to about amino acid 702 of the human full-length CEA (SEQ ID NO:2). Nucleotide sequences encoding hCEA- $\Delta$ AD of the present invention are codon-optimized for high-level expression in a human cellular environment (designated herein hCEAopt- $\Delta$ AD"). An exemplary DNA molecule encoding a CEA variant that is truncated of its anchoring domain is set forth in SEQ ID NO:15 (shown in FIGURE 10A). The corresponding amino acid sequence of hCEA- $\Delta$ AD is set forth in SEQ ID NO:16 (shown in FIGURE 10B). Nucleotides encoding hCEA- $\Delta$ AD are useful for the development of a cancer vaccine for treatment and/or prophylaxis of cancer.

The term "mammalian" refers to any mammal, including a human being.

The abbreviation "Ag" refers to an antigen.

The abbreviations "Ab" and "mAb" refer to an antibody and a monoclonal antibody, respectively.

The abbreviation "ORF" refers to the open reading frame of a gene.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows the nucleotide sequence of wild-type human CEA cDNA (SEQ ID NO:3) and of the codon optimized clone (hCEAopt, SEQ ID NO:1). The deduced amino acid sequence is shown on top (SEQ ID NO:2). The substituted nucleotides of the synthetic codon optimized cDNA are shown below the hCEA cDNA sequence. See EXAMPLE 2.

FIGURE 2 shows the expression of hCEA in injected mice. Groups of 10 C57BL/6 mice were injected in the quadriceps muscle either with various doses of MRKAd5-hCEA and MRKAd5-hCEAopt (Panel A) or with 25 or 50 micrograms of plasmids pV1J/hCEA and pV1J/hCEAopt (Panel B). Blood samples were collected 3 days postinjection and CEA levels were measured. Filled triangles represent CEA measurement of individual mice. Geometric mean values are also shown (filled circle).

FIGURE 3 shows that codon optimization increases the immune response to human CEA. Groups of 8 C57BL/6 mice were injected via the quadriceps muscle either with various doses of MRKAd5-hCEA and MRKAd5-hCEAopt. Virus injections were carried out at 0 and 21 days. Panel A.

At two weeks post boosting injection, the number of CD8<sup>+</sup> IFN $\gamma$  secreting T cells specific for hCEA was determined by ELISPOT assay on splenocytes from individual mice (filled triangles) using peptide 143 that covers aa 569-583 and includes a CD8<sup>+</sup> epitope. Two different amounts of splenocytes ( $2.5 \times 10^5$  and  $5 \times 10^5$ ) and two replicas of each tested amount of splenocytes. Average values were calculated by subtracting the background level determined in the absence of peptides (typically less than 10 SFC/10<sup>6</sup> total splenocytes), and the results were expressed as the number of SFC/10<sup>6</sup> total splenocytes. Values from individual mice are shown (filled triangles) as well as the geometric mean values (filled circle). Panel B. Anti-CEA antibody titers in sera from individual mice (filled triangles) were measured using 10 days post boost serum samples. Geometric mean titers (GMT) (filled circles) are also shown.

Ad/hCEAopt is significantly different from Ad/hCEA.

FIGURE 4. Comparison of different immunization regimens. Groups of C57BL/6 (A) or BALB/c (B) mice were immunized with different combinations of plasmid pV1J/hCEA (50 $\mu$ g/dose electroinjected in the quadriceps muscle) and MRKAd5/hCEA ( $1 \times 10^9$  pp/dose). The number of IFN $\gamma$ -secreting T cells in splenocytes in each individual mouse was determined using a pool of peptides covering aa 497-703 (pool D) as described in materials and methods and in the legend to FIGURE 3. Geometric mean values are also shown (filled circles). D/D and D/A are significantly different from Ad/Ad group in C57BL/6 mice. All three groups are significantly different in BALB/c mice.

FIGURE 5 shows the results of mapping of T-cell responses to selected regions of the hCEA protein. Groups of C57BL/6 (Panel A) or BALB/c (Panel B) mice were immunized with 50 $\mu$ g of plasmid pV1J/hCEA and boosted three weeks later with  $1 \times 10^9$  pp of Ad/hCEA. The number of IFN $\gamma$ -secreting T cells in splenocytes in each individual mouse was determined two weeks post-boost using pool of peptides covering the entire protein as described in materials and methods and in the legend to Figure 3. Geometric mean values are also shown (filled circles).

FIGURE 6. Identification of immunoresponsive peptides of hCEA. Pooled splenocytes from 4 immunized C57BL/6 (Panel A) or BALB/c (Panel B) mice were assayed for IFN $\gamma$  secretion against each indicated peptide by ELISPOT assay (see EXAMPLE 8).

FIGURE 7 shows the sequence of epitope containing peptides for CEA in C57BL/6 mice (Panel A) and BALB/c mice (Panel B) (see EXAMPLE xx). Listed to the right are the percent of IFN $\gamma$  producing CD8<sup>+</sup> (CD4<sup>+</sup>) CD3<sup>+</sup> cells.

FIGURE 8 shows results from an IFN $\gamma$ -ELISPOT assay of immunized CEA transgenic mice as described in EXAMPLE 9. Mice were immunized with four electroinjections of plasmid DNA one week apart plus one adenovirus injection. For each immunogen, data were obtained with pooled splenocytes of three injected mice. The CD8-specific response was measured using peptide 143.

FIGURE 9 shows IFN $\gamma$ -intracellular staining of immunized CEA.tg mice. Mice were immunized with 2 injections of  $1 \times 10^{10}$  vp of Adenovirus two weeks apart. Shown are the data obtained



with pooled splenocytes of three injected mice. Listed to the right are the percent of CD8<sup>+</sup> or CD4<sup>+</sup> cells.

FIGURE 10, Panel A, shows an exemplary codon-optimized DNA molecule encoding a CEA variant that is truncated of its anchoring domain as set forth in SEQ ID NO:15. The corresponding amino acid sequence of hCEA-ΔAD is shown in Panel B (SEQ ID NO:16).

#### DETAILED DESCRIPTION OF THE INVENTION

Carcinoembryonic antigen (CEA) is commonly associated with the development of adenocarcinomas. The present invention relates to compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with the carcinoma or its development. Association of aberrant CEA expression with a carcinoma does not require that the CEA protein be expressed in tumor tissue at all timepoints of its development, as abnormal CEA expression may be present at tumor initiation and not be detectable late into tumor progression or vice-versa.

To this end, synthetic DNA molecules encoding the human CEA protein are provided. The codons of the synthetic molecules are designed so as to use the codons preferred by the projected host cell, which in preferred embodiments is a human cell. The synthetic molecules may be used for the development of recombinant adenovirus or plasmid-based vaccines, which provide effective immunoprophylaxis against CEA-associated cancer through neutralizing antibody and cell-mediated immunity. The synthetic molecules may be used as an immunogenic composition. This invention provides polynucleotides which, when directly introduced into a vertebrate *in vivo*, including mammals such as primates and humans, induce the expression of encoded proteins within the animal.

The wild-type human CEA nucleotide sequence has been reported (*See, e.g.*, U.S. Patent No. 5,274,087; U.S. Patent No 5,571,710; and U.S. Patent No 5,843,761). The present invention provides synthetic DNA molecules encoding the human CEA protein. The synthetic molecules of the present invention comprise a sequence of nucleotides, wherein some of the nucleotides have been altered so as to use the codons preferred by a human cell, thus allowing for high-level expression of CEA in a human host cell. The synthetic molecules may be used as a source of CEA protein, which may be used in a cancer vaccine to provide effective immunoprophylaxis against CEA-associated carcinomas through neutralizing antibody and cell-mediated immunity.

A "triplet" codon of four possible nucleotide bases can exist in over 60 variant forms. Because these codons provide the message for only 20 different amino acids (as well as transcription initiation and termination), some amino acids can be coded for by more than one codon, a phenomenon known as codon redundancy. For reasons not completely understood, alternative codons are not uniformly present in the endogenous DNA of differing types of cells. Indeed, there appears to exist a

variable natural hierarchy or "preference" for certain codons in certain types of cells. As one example, the amino acid leucine is specified by any of six DNA codons including CTA, CTC, CTG, CTT, TTA, and TTG. Exhaustive analysis of genome codon frequencies for microorganisms has revealed endogenous DNA of *E. coli* most commonly contains the CTG leucine-specifying codon, while the DNA of yeasts and slime molds most commonly includes a TTA leucine-specifying codon. In view of this hierarchy, it is generally believed that the likelihood of obtaining high levels of expression of a leucine-rich polypeptide by an *E. coli* host will depend to some extent on the frequency of codon use. For example, it is likely that a gene rich in TTA codons will be poorly expressed in *E. coli*, whereas a CTG rich gene will probably be highly expressed in this host. Similarly, a preferred codon for expression of a leucine-rich polypeptide in yeast host cells would be TTA.

The implications of codon preference phenomena on recombinant DNA techniques are manifest, and the phenomenon may serve to explain many prior failures to achieve high expression levels of exogenous genes in successfully transformed host organisms—a less "preferred" codon may be repeatedly present in the inserted gene and the host cell machinery for expression may not operate as efficiently. This phenomenon suggests that synthetic genes which have been designed to include a projected host cell's preferred codons provide an optimal form of foreign genetic material for practice of recombinant DNA techniques. Thus, one aspect of this invention is a human CEA gene that is codon-optimized for expression in a human cell. In a preferred embodiment of this invention, it has been found that the use of alternative codons encoding the same protein sequence may remove the constraints on expression of exogenous CEA protein in human cells.

In accordance with this invention, the human CEA gene sequence was converted to a polynucleotide sequence having an identical translated sequence but with alternative codon usage as described by Lathe, "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data: Theoretical and Practical Considerations" *J. Molec. Biol.* 183:1-12 (1985), which is hereby incorporated by reference. The methodology generally consists of identifying codons in the wild-type sequence that are not commonly associated with highly expressed human genes and replacing them with optimal codons for high expression in human cells. The new gene sequence is then inspected for undesired sequences generated by these codon replacements (e.g., "ATTTA" sequences, inadvertent creation of intron splice recognition sites, unwanted restriction enzyme sites, etc.). Undesirable sequences are eliminated by substitution of the existing codons with different codons coding for the same amino acid. The synthetic gene segments are then tested for improved expression.

The methods described above were used to create synthetic gene sequences for human CEA, resulting in a gene comprising codons optimized for high level expression. While the above procedure provides a summary of our methodology for designing codon-optimized genes for use in cancer vaccines, it is understood by one skilled in the art that similar vaccine efficacy or increased

expression of genes may be achieved by minor variations in the procedure or by minor variations in the sequence. One of skill in the art will also recognize that additional DNA molecules may be constructed that provide for high levels of CEA expression in human cells, wherein only a portion of the codons of the DNA molecules are codon-optimized.

5                   Accordingly, the present invention relates to a synthetic polynucleotide comprising a sequence of nucleotides encoding a human CEA protein (SEQ ID NO:2), or a biologically active fragment or mutant form of a human CEA protein, including, but not limited to hCEA-ΔAD (SEQ ID NO:16), the polynucleotide sequence comprising codons optimized for expression in a human host. Said mutant forms of the CEA protein include, but are not limited to: conservative amino acid substitutions, amino-terminal truncations, carboxy-terminal truncations, deletions, or additions, collectively referred to  
10                   herein as "variants". Any such biologically active fragment and/or mutant will encode either a protein or protein fragment which at least substantially mimics the immunological properties of the CEA protein as set forth in SEQ ID NO:2. The synthetic polynucleotides of the present invention encode mRNA molecules that express a functional human CEA protein so as to be useful in the development of a  
15                   therapeutic or prophylactic cancer vaccine.

                  As stated above, the present invention relates to nucleotides encoding a human CEA protein (SEQ ID NO:2), or a biologically active fragment or mutant form thereof. To this end, the present invention provides nucleotides encoding hCEA-ΔAD (SEQ ID NO:16, FIGURE 10B), which comprises a human CEA protein that is deleted of its C-terminal anchoring sequence. The nucleic acid molecules of  
20                   the present invention encoding hCEA-ΔAD are codon-optimized for enhanced expression in human cells. An exemplary nucleic acid molecule encoding hCEA-ΔAD comprises a sequence of nucleotides as set forth in SEQ ID NO:15 (FIGURE 10A).

                  The present invention relates to an synthetic nucleic acid molecule (polynucleotide) comprising a sequence of nucleotides which encodes mRNA that expresses a novel hCEA protein as set  
25                   forth in SEQ ID NO:2, wherein the synthetic nucleic acid molecule is codon-optimized for high-level expression in a human host cell. The nucleic acid molecules of the present invention are substantially free from other nucleic acids.

                  The present invention also relates to recombinant vectors and recombinant host cells, both prokaryotic and eukaryotic, which contain the nucleic acid molecules disclosed throughout this  
30                   specification. The synthetic DNA molecules, associated vectors, and hosts of the present invention are useful for the development of a cancer vaccine.

                  A preferred DNA molecule of the present invention comprises the nucleotide sequence disclosed herein as SEQ ID NO:1, shown in FIGURE 1, which encodes the human CEA protein shown in FIGURE 2 and set forth as SEQ ID NO:2.

A further preferred DNA molecule of the present invention comprises the nucleotide sequence disclosed herein as SEQ ID NO:15, shown in FIGURE 10A, which encodes a human CEA variant that is deleted of its C-terminal anchoring sequence, as set forth in SEQ ID NO:16, and shown in FIGURE 10B.

5           The present invention also includes biologically active fragments or mutants of SEQ ID NOs:1, which encode mRNA expressing human CEA proteins. Any such biologically active fragment and/or mutant will encode either a protein or protein fragment which at least substantially mimics the pharmacological properties of the hCEA protein, including but not limited to the hCEA protein as set forth in SEQ ID NO:2. Any such polynucleotide includes but is not necessarily limited to: nucleotide  
10       substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations. The mutations of the present invention encode mRNA molecules that express a functional hCEA protein in a eukaryotic cell so as to be useful in cancer vaccine development.

          This invention also relates to synthetic codon-optimized DNA molecules that encode the hCEA protein wherein the nucleotide sequence of the synthetic DNA differs significantly from the  
15       nucleotide sequence of SEQ ID NO:1, but still encodes the hCEA protein as set forth in SEQ ID NO:2. Such synthetic DNAs are intended to be within the scope of the present invention. Therefore, the present invention discloses codon redundancy that may result in numerous DNA molecules expressing an identical protein. Also included within the scope of this invention are mutations in the DNA sequence that do not substantially alter the ultimate physical properties of the expressed protein. For example,  
20       substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in the functionality of the polypeptide.

          It is known that DNA sequences coding for a peptide may be altered so as to code for a peptide that has properties that are different than those of the naturally occurring peptide. Methods of altering the DNA sequences include but are not limited to site directed mutagenesis. Examples of altered  
25       properties include but are not limited to changes in the affinity of an enzyme for a substrate or receptor for a ligand.

          The present invention also relates to hCEAopt fusion constructs, including but not limited to fusion constructs which express a portion of the human CEA protein linked to various markers, including but in no way limited to GFP (Green fluorescent protein), the MYC epitope, GST, and Fc. Any  
30       such fusion construct may be expressed in the cell line of interest and used to screen for modulators of the human CEA protein disclosed herein. Also contemplated are fusion constructs that are constructed to enhance the immune response to human CEA including, but not limited to: DOM and hsp70, and LTB.

          The present invention further relates to recombinant vectors that comprise the synthetic nucleic acid molecules disclosed throughout this specification. These vectors may be comprised of DNA  
35       or RNA. For most cloning purposes, DNA vectors are preferred. Typical vectors include plasmids,

modified viruses, baculovirus, bacteriophage, cosmids, yeast artificial chromosomes, and other forms of episomal or integrated DNA that can encode a hCEA protein. It is well within the purview of the skilled artisan to determine an appropriate vector for a particular gene transfer or other use.

5 An expression vector containing codon-optimized DNA encoding a hCEA protein may be used for high-level expression of hCEA in a recombinant host cell. Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses. Also, a variety of bacterial expression vectors may be used to express recombinant hCEA in bacterial cells if desired. In addition, a variety of fungal cell expression vectors may be used to express recombinant hCEA in fungal cells. Further, a variety of insect cell expression vectors may be used to  
10 express recombinant protein in insect cells.

The present invention also relates to host cells transformed or transfected with vectors comprising the nucleic acid molecules of the present invention. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of bovine, porcine, monkey and rodent origin;  
15 and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Such recombinant host cells can be cultured under suitable conditions to produce hCEA or a biologically equivalent form. In a preferred embodiment of the present invention, the host cell is human. As defined herein, the term "host cell" is not intended to include a host cell in the body of a transgenic human being, human fetus, or human embryos.

20 As noted above, an expression vector containing DNA encoding a hCEA protein may be used for expression of hCEA in a recombinant host cell. Therefore, another aspect of this invention is a process for expressing a human CEA protein or protein variant in a recombinant host cell, comprising: (a) introducing a vector comprising a nucleic acid as set forth in SEQ ID NO:1 or SEQ ID NO:15 into a suitable human host cell; and, (b) culturing the host cell under conditions which allow expression of said  
25 human CEA protein or CEA protein variant.

Following expression of hCEA in a host cell, hCEA protein may be recovered to provide hCEA protein in active form. Several hCEA protein purification procedures are available and suitable for use. Recombinant hCEA protein may be purified from cell lysates and extracts by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion  
30 chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography. In addition, recombinant hCEA protein can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for full-length hCEA protein, or polypeptide fragments of hCEA protein.

The nucleic acids of the present invention may be assembled into an expression cassette  
35 which comprises sequences designed to provide for efficient expression of the protein in a human cell.

The cassette preferably contains a full-length codon-optimized hCEA gene, with related transcriptional and translations control sequences operatively linked to it, such as a promoter, and termination sequences. In a preferred embodiment, the promoter is the cytomegalovirus promoter without the intron A sequence (CMV), although those skilled in the art will recognize that any of a number of other known promoters  
5 such as the strong immunoglobulin, or other eukaryotic gene promoters may be used. A preferred transcriptional terminator is the bovine growth hormone terminator, although other known transcriptional terminators may also be used. The combination of CMV-BGH terminator is particularly preferred.

In accordance with this invention, the hCEAopt expression cassette is inserted into a vector. The vector is preferably an adenoviral vector, although linear DNA linked to a promoter, or other  
10 vectors, such as adeno-associated virus or a modified vaccinia virus, retroviral or lentiviral vector may also be used.

If the vector chosen is an adenovirus, it is preferred that the vector be a so-called first-generation adenoviral vector. These adenoviral vectors are characterized by having a non-functional E1 gene region, and preferably a deleted adenoviral E1 gene region. In some embodiments, the expression  
15 cassette is inserted in the position where the adenoviral E1 gene is normally located. In addition, these vectors optionally have a non-functional or deleted E3 region. It is preferred that the adenovirus genome used be deleted of both the E1 and E3 regions ( $\Delta E1\Delta E3$ ). The adenoviruses can be multiplied in known cell lines which express the viral E1 gene, such as 293 cells, or PERC.6 cells, or in cell lines derived from 293 or PERC.6 cell which are transiently or stably transformed to express an extra protein. For  
20 examples, when using constructs that have a controlled gene expression, such as a tetracycline regulatable promoter system, the cell line may express components involved in the regulatory system. One example of such a cell line is T-Rex-293; others are known in the art.

For convenience in manipulating the adenoviral vector, the adenovirus may be in a shuttle plasmid form. This invention is also directed to a shuttle plasmid vector which comprises a  
25 plasmid portion and an adenovirus portion, the adenovirus portion comprising an adenoviral genome which has a deleted E1 and optional E3 deletion, and has an inserted expression cassette comprising codon-optimized human CEA. In preferred embodiments, there is a restriction site flanking the adenoviral portion of the plasmid so that the adenoviral vector can easily be removed. The shuttle plasmid may be replicated in prokaryotic cells or eukaryotic cells.

In a preferred embodiment of the invention, the expression cassette is inserted into the  
30 pMRKAd5-HV0 adenovirus plasmid (*See* Emini et al., WO 02/22080, which is hereby incorporated by reference). This plasmid comprises an Ad5 adenoviral genome deleted of the E1 and E3 regions. The design of the pMRKAd5-HV0 plasmid was improved over prior adenovectors by extending the 5' cis-acting packaging region further into the E1 gene to incorporate elements found to be important in

optimizing viral packaging, resulting in enhanced virus amplification. Advantageously, this enhanced adenoviral vector is capable of maintaining genetic stability following high passage propagation.

Standard techniques of molecular biology for preparing and purifying DNA constructs enable the preparation of the adenoviruses, shuttle plasmids, and DNA immunogens of this invention.

5 It has been determined in accordance with the present invention that the synthetic cDNA molecule described herein (SEQ ID NO:1), which is codon-optimized for high-level expression in a human cell, is expressed with greater efficiency than the corresponding wild type sequence. Surprisingly, the codon optimized cDNA of hCEA breaks tolerance to hCEA more efficiently than the wild type sequence. Additionally, it was shown herein that hCEAopt is more immunogenic than hCEA and is more  
10 efficient in eliciting both cellular and humoral immune responses.

Therefore, the vectors described above may be used in immunogenic compositions and vaccines for preventing the development of adenocarcinomas associated with aberrant CEA expression and/or for treating existing cancers. The vectors of the present invention allow for vaccine development and commercialization by eliminating difficulties with obtaining high expression levels of exogenous  
15 CEA in successfully transformed host organisms. To this end, one aspect of the instant invention is a method of preventing or treating cancer comprising administering to a mammal a vaccine vector comprising a synthetic codon-optimized nucleic acid molecule, the synthetic codon-optimized nucleic acid molecule comprising a sequence of nucleotides that encodes a human CEA protein as set forth in SEQ ID NO:2.

20 In accordance with the method described above, the vaccine vector may be administered for the treatment or prevention of cancer in any mammal. In a preferred embodiment of the invention, the mammal is a human.

Further, one of skill in the art may choose any type of vector for use in the treatment and prevention method described. Preferably, the vector is an adenovirus vector or a plasmid vector. In a  
25 preferred embodiment of the invention, the vector is an adenoviral vector comprising an adenoviral genome with a deletion in the adenovirus E1 region, and an insert in the adenovirus E1 region, wherein the insert comprises an expression cassette comprising: (a) a synthetic codon-optimized polynucleotide encoding a human CEA protein; and (b) a promoter operably linked to the polynucleotide.

The instant invention further relates to an adenovirus vaccine vector comprising an  
30 adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising: (a) a synthetic codon-optimized polynucleotide encoding a human CEA protein; and (b) a promoter operably linked to the polynucleotide.

In a preferred embodiment of this aspect of the invention, the adenovirus vector is an Ad  
5 vector.

In another preferred embodiment of the invention, the adenovirus vector is an Ad 6 vector.

In yet another preferred embodiment, the adenovirus vector is an Ad 24 vector.

In another aspect, the invention relates to a vaccine plasmid comprising a plasmid portion  
5 and an expression cassette portion, the expression cassette portion comprising: (a) a synthetic codon-optimized polynucleotide encoding a human CEA protein or variant thereof; and (b) a promoter operably linked to the polynucleotide.

In some embodiments of this invention, the recombinant adenovirus vaccines disclosed herein are used in various prime/boost combinations with a plasmid-based polynucleotide vaccine in  
10 order to induce an enhanced immune response. In this case, the two vectors are administered in a "prime and boost" regimen. For example the first type of vector is administered, then after a predetermined amount of time, for example, 2 weeks, 1 month, 2 months, six months, or other appropriate interval, a second type of vector is administered. Preferably the vectors carry expression cassettes encoding the same polynucleotide or combination of polynucleotides. In the embodiment where a plasmid DNA is  
15 also used, it is preferred that the vector contain one or more promoters recognized by mammalian or insect cells. In a preferred embodiment, the plasmid would contain a strong promoter such as, but not limited to, the CMV promoter. The synthetic human CEA gene or other gene to be expressed would be linked to such a promoter. An example of such a plasmid would be the mammalian expression plasmid V1Jns as described (J. Shiver *et. al.* in *DNA Vaccines*, M. Liu et al. eds., N.Y. Acad. Sci., N.Y., 772:198-  
20 208 (1996), which is herein incorporated by reference).

As stated above, an adenoviral vector vaccine and a plasmid vaccine may be administered to a vertebrate as part of a single therapeutic regime to induce an immune response. To this end, the present invention relates to a method of protecting a mammal from cancer comprising: (a)  
25 introducing into the mammal a first vector comprising: i) a synthetic codon-optimized polynucleotide encoding a human CEA protein or human CEA protein variant; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and (c) introducing into the mammal a second vector comprising: i) a synthetic codon-optimized polynucleotide encoding a human CEA protein or human CEA protein variant; and ii) a promoter operably linked to the polynucleotide.

In one embodiment of the method of protection described above, the first vector is a  
30 plasmid and the second vector is an adenovirus vector. In an alternative embodiment, the first vector is an adenovirus vector and the second vector is a plasmid.

The instant invention further relates to a method of treating a mammal suffering from an adenocarcinoma comprising: (a) introducing into the mammal a first vector comprising: i) a synthetic  
35 codon-optimized polynucleotide encoding a human CEA protein or human CEA protein variant; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and



(c) introducing into the mammal a second vector comprising: i) a synthetic codon-optimized polynucleotide encoding a human CEA protein or human CEA protein variant; and ii) a promoter operably linked to the polynucleotide.

In one embodiment of the method of treatment described above, the first vector is a plasmid and the second vector is an adenovirus vector. In an alternative embodiment, the first vector is an adenovirus vector and the second vector is a plasmid.

The amount of expressible DNA or transcribed RNA to be introduced into a vaccine recipient will depend partially on the strength of the promoters used and on the immunogenicity of the expressed gene product. In general, an immunologically or prophylactically effective dose of about 1 ng to 100 mg, and preferably about 10 µg to 300 µg of a plasmid vaccine vector is administered directly into muscle tissue. An effective dose for recombinant adenovirus is approximately  $10^6$  –  $10^{12}$  particles and preferably about  $10^7$ — $10^{11}$  particles. Subcutaneous injection, intradermal introduction, impression through the skin, and other modes of administration such as intraperitoneal, intravenous, or inhalation delivery are also contemplated. It is also contemplated that booster vaccinations may be provided. Parenteral administration, such as intravenous, intramuscular, subcutaneous or other means of administration with adjuvants such as interleukin 12 protein, concurrently with or subsequent to parenteral introduction of the vaccine of this invention is also advantageous.

The vaccine vectors of this invention may be naked, i.e., unassociated with any proteins, adjuvants or other agents which impact on the recipient's immune system. In this case, it is desirable for the vaccine vectors to be in a physiologically acceptable solution, such as, but not limited to, sterile saline or sterile buffered saline. Alternatively, it may be advantageous to administer an immunostimulant, such as an adjuvant, cytokine, protein, or other carrier with the vaccines or immunogenic compositions of the present invention. Therefore, this invention includes the use of such immunostimulants in conjunction with the compositions and methods of the present invention. An immunostimulant, as used herein, refers to essentially any substance that enhances or potentiates an immune response (antibody and/or cell-mediated) to an exogenous antigen. Said immunostimulants can be administered in the form of DNA or protein. Any of a variety of immunostimulants may be employed in conjunction with the vaccines and immunogenic compositions of the present inventions, including, but not limited to: GM-CSF, IFN $\alpha$ , tetanus toxoid, IL12, B7.1, LFA-3 and ICAM-1. Said immunostimulants are well-known in the art. Agents which assist in the cellular uptake of DNA, such as, but not limited to calcium ion, may also be used. These agents are generally referred to as transfection facilitating reagents and pharmaceutically acceptable carriers. Those of skill in the art will be able to determine the particular immunostimulant or pharmaceutically acceptable carrier as well as the appropriate time and mode of administration.

All publications mentioned herein are incorporated by reference for the purpose of describing and disclosing methodologies and materials that might be used in connection with the present invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

5 Having described preferred embodiments of the invention with reference to the accompanying drawings, it is to be understood that the invention is not limited to those precise embodiments, and that various changes and modifications may be effected therein by one skilled in the art without departing from the scope or spirit of the invention as defined in the appended claims.

The following examples illustrate, but do not limit the invention.

10

#### EXAMPLE 1

Human CEA optimized codon sequence.

The entire hCEAopt coding sequence was synthesized and assembled by BIONEXUS (Oakland, CA). The hCEAopt cDNA, which carries an optimized Kozak sequence at its 5'-end, was constructed using oligonucleotides assembled by PCR. The assembled cDNA was inserted into the pCR-Blunt vector (Invitrogen, Carlsbad, CA), yielding pCR-hCEAopt. The integrity of the hCEAopt cDNA was determined by sequencing of both strands.

#### EXAMPLE 2

20 Plasmid Constructs and Adenovirus vectors.

pV1J/hCEAopt: Plasmid pCR-hCEAopt was digested with *EcoRI* for 1 hr at 37°C. The resulting 2156 bp insert was purified and cloned into the *EcoRI* site of plasmid pV1JnsB (Montgomery, et al., *DNA Cell Biol.*, 12(9):777-83(1993)).

pV1J/hCEA: Plasmid pCI/hCEA (Song et al. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumour immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. *Gene Therapy* 7: 481-492 (2000)) was digested with *EcoRI*. The resulting 2109 bp insert was cloned into the *EcoRI* site of plasmid pV1JnsA (Montgomery et al., *supra*).

Ad5/hCEAopt: Plasmid pCR-hCEAopt was digested with *EcoRI*. The resulting 2156 bp insert was purified and cloned into the *EcoRI* of the polyMRK-Ad5 shuttle plasmid (See Emini et al., WO 02/22080, which is hereby incorporated by reference).

Ad5/CEA: The shuttle plasmid pMRK-hCEA for generation of Ad5 vector was obtained by digesting plasmid pDelta1sp1B/hCEA with *SspI* and *EcoRV*. The 9.52 kb fragment was then ligated with a 1272 bp *BglII-BamHI* restricted, Klenow treated product from plasmid polyMRK. A *PacI/StuI* fragment from pMRK-hCEA and pMRK-hCEAopt containing the expression cassette for hCEA and E1 flanking Ad5 regions was recombined to *ClaI* linearized plasmid pAd5 in BJ5183 *E. coli* cells. The

35

resulting plasmids were pAd5-hCEA and pAd5-hCEAopt, respectively. Both plasmids were cut with *PacI* to release the Ad inverted terminal repeats (ITRs) and transfected in PerC-6 cells. Ad5 vectors amplification was carried out by serial passage. MRKAd5/hCEA and MRKAd5/hCEAopt were purified through standard CsCl gradient purification and extensively dialyzed against A105 buffer (5mM Tris-Cl  
5 pH 8.0, 1mM MgCl<sub>2</sub>, 75 mM NaCl, 5% Sucrose, 0.005 Tween 20).

### EXAMPLE 3

#### CEA Expression and Detection.

Expression of hCEA by the plasmid and Ad vectors was monitored by Western blot  
10 analysis. Plasmids were transfected in HeLa cells or PerC.6 cells with Lipofectamine 2000 (Life Technologies, Carlsbad, CA). Adenovirus infections of PerC.6 cells were performed in serum free medium for 30 min at 37° C, then fresh medium was added. After 48 hr incubation, whole cell lysates and culture supernatant were harvested. The CEA protein present in the cell lysates was detected by  
15 Western blot analysis using a rabbit polyclonal antiserum. The protein was detected as a 180-200 kDa band. The secreted CEA was detected in the cell supernatants and in peripheral blood of injected mice (3 days post injection) using the Direct Elisa CEA Kit (DBC-Diagnostics Biochem Canada Inc., Ontario, Canada).

### EXAMPLE 4

#### Mice immunization.

Female C57BL/6 mice (H-2b) were purchased from Charles River (Lecco, Italy).  
CEA.tg mice (H-2b) were provided by J. Primus (Vanderbilt University) and kept in standard conditions. Fifty micrograms of plasmid DNA were electroinjected in a 50µl volume in mice quadriceps as  
previously described (Rizzuto et al. *Proc. Natl. Acad. Sci. U.S.A.* 96(11): 6417-22 (1999)). Ad injections  
25 were carried out in mice quadriceps in 50 µl volume. Humoral and cell mediated immune response were analyzed at the indicated time.

### EXAMPLE 5

Codon optimized cDNA of hCEA significantly increased hCEA expression.

30 A synthetic gene of human CEA (hCEAopt) was designed to incorporate human-preferred (humanized) codons for each amino acid (hereinafter aa) residue. The codon optimized cDNA was modified to maintain 76.8% nucleotide identity to the original clone (see FIGURE 1). The codon optimized cDNAs were cloned into the pV1J vectors (Montgomery et al., *supra*), placing in front a Kozak optimized sequence (5'-GCCGCCACC-3', SEQ ID NO:13) and under the control of the human  
35 cytomegalovirus (CMV)/intron A promoter plus the bovine growth hormone (BGH) termination signal.

The construct was named pV1J/hCEAopt (see EXAMPLE 2). Additionally, an Adenovirus type 5 vector was constructed carrying the hCEAopt sequence flanked by the CMV/intron A promoter and the BGH termination signal (Ad5/hCEAopt). For comparison, the equivalent plasmid and Ad5 vectors were constructed carrying the wild type hCEA sequence yielding pV1J/hCEA and Ad5/hCEA. Similar to those  
5 containing the codon optimized cDNA, these vectors carry the wild type gene under the control of the CMV/int A promoter with BGH termination signal.

Western blot analysis of HeLa cells transfected with plasmid pV1J/hCEAopt yielded a protein with large molecular mass (180-200 kDa) that was indistinguishable in size from that detected in cells transfected with construct pV1J/hCEA. Similarly, no apparent differences could be detected in the  
10 size of the protein detected in PerC-6 cell lysates that had been infected with Ad5/hCEA or Ad5H7hCEAopt (data not shown).

To compare the efficiency of expression of the hCEAopt to that of hCEA, groups of 10 C57BL/6 mice were injected into the quadriceps with different doses of the Ad5/hCEAopt vector ranging from  $1 \times 10^7$  to  $1 \times 10^4$  pfu. Three days post injection, CEA protein levels were determined and compared  
15 to those of control groups that had been injected with the same doses of Ad5/hCEA. A sixfold increase in the geometric mean values of hCEA levels was observed upon injection of  $1 \times 10^7$  pfu of Ad/hCEAopt (48.2  $\mu\text{g/l}$ ) relative to the Ad5/hCEA injected mice, whereas a tenfold increase in protein level was observed upon injection of  $1 \times 10^6$  pfu of the same virus (19.1  $\mu\text{g/l}$ ) (FIGURE 2A). In contrast, injection of lower doses of Ad5/hCEAopt did not result in a substantial increase in circulating CEA levels as  
20 compared to Ad5/hCEA. The enhancement of CEA protein levels was also noted, albeit to a lower extent, upon electroinjection of 25 or 50  $\mu\text{g}$  of plasmid pV1J/hCEAopt relative to pV1J/hCEA (FIGURE 2B). Thus, these results indicate that, independently of the gene transfer vehicle utilized, the codon optimized cDNA is expressed with greater efficiency than the corresponding wild type sequence.

25

## EXAMPLE 6

IFN- $\gamma$  ELISPOT Assay.

Ninety-six wells MAIP plates (Millipore, Bedford, MA) were coated with 100  $\mu\text{l}$ / well of purified rat anti-mouse IFN- $\gamma$  (IgG1, clone R4-6A2, Pharmingen, San Diego, CA) diluted to 2.5  $\mu\text{g/ml}$  in sterile PBS. After washing with PBS, blocking of plates was carried out with 200  $\mu\text{l}$ /well of R10 medium  
30 for 2 hrs at 37°C.

Splenocytes were obtained by removing the spleen from the euthanized mice in a sterile manner. Spleen disruption was carried out by grating the dissected spleen on a metal grid. Red blood cells were removed by osmotic lysis by adding 1 ml of 0.1X PBS to the cell pellet and vortexing no more than 15 seconds. One ml of 2X PBS was then added and the volume was brought to 4 ml with 1X PBS.

Cells were pelleted by centrifugation at 1200 rpm for 10 min at room temp., and the pellet was resuspended in 1 ml R10 medium. Viable cells were counted using Türks staining.

Splenocytes were plated at  $5 \times 10^5$  and  $2 \times 10^5$  cells/well in duplicate and incubated for 20 h at 37°C with 1 µg/ml suspension of each peptide. Concanavalin A (ConA) was used as positive internal control for each mouse at 5 µg/ml. After washing with PBS, 0.05% Tween 20, plates were incubated O/N at 4°C with 50 µl/well of biotin-conjugated rat anti-mouse IFN $\gamma$  (RatIgG1, clone XMG 1.2, PharMingen) diluted to 1:2500 in Assay buffer. After extensive washing, plates were developed by adding 50 µl/well NBT/B-CIP (Pierce Biotechnology Inc., Rockford, IL) until development of spots was clearly visible. The reaction was stopped by washing plates thoroughly with distilled water. Plates were air dried and spots were then counted using an automated ELISPOT reader.

#### EXAMPLE 7

##### Intracellular Cytokine Staining.

One to two million mouse splenocytes or PBMC in 1ml RPMI 10% FCS were incubated with a pool of peptides (5-6 µg/ml final concentration of each peptide) and brefeldin A (1 µg/ml; BD Pharmingen cat #555028/2300kk) and 5% CO $_2$  for 12-16 hours at 37°C. Cells were then washed with FACS buffer (PBS 1% FBS, 0.01% NaN $_3$ ) and incubated with purified anti-mouse CD16/CD32 Fc block (BD Pharmingen cat # 553142) for 15 min at 4°C. Cells were then washed and stained with surface antibodies: CD4-PE conjugated anti-mouse (BD Pharmingen, cat.# 553049), PercP CD8 conjugated anti mouse (BD Pharmingen cat# 553036) and APC- conjugated anti-mouse CD3e (BD Pharmingen cat# 553066) for 30 minutes at room temperature in the dark. After the washing, cells were fixed and permeabilized with Cytofix-Cytoperm Solution (BD Pharmingen cat #555028/2300kk) for 20 min at 4°C in the dark. After washing with PermWash Solution (BD Pharmingen cat #555028/2300kk) cells were incubated with the IFN $\gamma$ -FITC antibodies (BD Pharmingen). Cells were then washed, fixed with formaldehyde 1% in PBS and analyzed on a FACS-Calibur flow cytometer, using CellQuest software (Becton Dickinson, San Jose, CA).

#### EXAMPLE 8

Identification and characterization of epitope containing peptides for direct enumeration of CEA-specific T cells

To better characterize the immune response elicited upon genetic vaccination against CEA in mice, ELISPOT analysis was carried out on C57BL/6 and BALB/c mice to identify CD4 $^+$  and CD8 $^+$  CEA specific epitopes. To this end, different immunization modalities were compared to generate highly immunized mice that could be utilized to identify responses to individual peptides that cover the entire protein. In view of recent reports that indicate that high levels of cellular immunity can be induced

against viral and bacterial antigens by utilizing plasmid DNA prime-Ad boost modality, the same immunization protocol was employed in this study. Mice were immunized intramuscularly by different regimens: i) two doses of  $1 \times 10^9$  vp of Ad/hCEA (Ad/Ad), ii) two doses of plasmid pV1J/hCEA (DNA/DNA) and iii) a dose of plasmid DNA followed by Ad/hCEA (DNA/Ad). The immunizations were two weeks apart.

The cellular immunity elicited by the different immunization regimes was measured by ELISPOT assay 2 weeks after the boost. To compare the immunogenic efficiency of the different vaccination regimens, a pool of 15mer peptides overlapping by 11 aa and covering aa 497-703 (pool D) were used to stimulate antigen specific cytokine secretion from splenocytes. The most vigorous responses, indicated by the higher geometric mean values of the SFC, were observed in C57BL/6 and BALB/c mice from the DNA/Ad injected group (FIGURE 4). Thus, this regimen was utilized to further analyze the immune response.

To determine whether the immune response was equally distributed across the entire CEA protein, splenocytes from immunized C57BL/6 and BALB/c mice were stimulated in vitro with one of four pools of 15-mer peptides that collectively encompass the entire protein sequence. Each pool consisted of peptides 15 amino acids long that overlap by 11 residues. Lyophilized hCEA peptides were purchased from Bio-Synthesis (Lewisville, TX) and resuspended in DMSO at 40 mg/ml. In addition to pool D, pools A (aa 1 to 147), B (aa 137 to 237), and C (aa 317 to 507) were used in this study. Final concentrations were the following: pool A=1.2 mg/ml, pool B= 0.89 mg/ml, pool C= 0.89 mg/ml, pool D= 0.8 mg/ml. Peptides were stored at  $-80^\circ\text{C}$ .

The immune response elicited by the DNA/Ad vaccination regimen in C57BL/6 mice was primarily biased towards the C-terminal region of the protein (see FIGURE 5A). Significant SFC values were obtained with peptide pool C and D (geometric mean values: 170 and 244 SFC/ $10^6$  splenocytes, respectively), whereas pool A and B yielded much lower values (10 and 27 SFC/ $10^6$  splenocytes, respectively). In contrast, the immune response in BALB/c mice was highest with pool B (geometric mean value: 1236 SFC/ $10^6$  splenocytes), although pool A, C, and D showed significant SFC values (93, 263, and 344 respectively) (FIGURE 5B). No responses against a pool of unrelated peptides were noted in both groups of mice (data not shown).

To identify the individual peptides present in the peptide pools that elicit the responses, spleens from 4 mice immunized with the DNA/Ad vaccination regimen were analyzed in a IFN $\gamma$ -ELISPOT assay against each of the individual peptides comprising the pools against which a significant immune response had been observed. Splenocytes from C57BL/6 mice were tested against peptides 80 to 173 included in pool C and D. Splenocytes from BALB/c mice were tested against peptides 35 to 173 that comprise pools B, C, and D. CEA specific responses in C57BL/6 mice were mapped to four pairs of 15-mer peptides that had overlapping sequences (aa 431 to 435 and 425 to 439; 529 to 543, and 533 to

547; 565 to 579, and 569 to 593; 613 to 627 and 617 to 631) (FIGURE 6A). The immune response to CEA in BALB/c mice was mapped to 22 different peptides, 17 of which have overlapping sequences (aa 213 to 227, and 213 and 227; 229 to 243, and 233 to 247; 409 to 423 and 413 to 427; 421 to 435 and 425 to 439; 565 to 579 and 569 to 583; 573 to 587; 613 to 627 and 617 to 631, and 621 to 635 and 625 to 639; 637 to 651 and 641 to 655) (FIGURE 6B).

To define the T-cell specificity of the epitopes contained within the selected peptides, IFN $\gamma$  intracellular staining assay was carried out on splenocytes from injected mice. The results obtained are shown in FIGURE 7. The data indicate that CD8 $^{+}$  and CD4 $^{+}$  specific epitopes have been identified for both C57BL/6 and BALB/c which can be used to quantify circulating levels of T-lymphocytes.

#### EXAMPLE 9

Codon optimized hCEA cDNA breaks tolerance in hCEA transgenic mice.

To determine whether the enhanced immunogenic properties of the codon optimized cDNA of hCEA would break tolerance to human CEA more efficiently, hCEA transgenic mice were immunized with vectors carrying either the wild type or the codon optimized hCEA sequences. These transgenic mice carry the entire human CEA gene plus flanking sequences and express the hCEA protein in the cecum and colon. Thus, this mouse line is a useful model for studying the safety and efficacy of immunotherapy strategies directed against this tumor self antigen (Clarke et al. Mice transgenic for human CEA as a model for immunotherapy. *Cancer Res.* 58(7): 1469-77 (1998)).

As a first test, groups of 5 to 10 transgenic mice were subjected to four electroinjections of 50  $\mu$ g plasmid DNA followed by a final injection of  $1 \times 10^{10}$  pp of Adenovirus. The immune response to hCEA was analyzed by IFN $\gamma$ -ELISPOT assay on pooled splenocytes from 4 injected mice. The immune response to hCEA was detected only with the splenocytes from the mice immunized with the hCEAopt cDNA (see FIGURE 8). The immune response was detected with peptides 143 and pool D, suggesting that immunization had elicited a significant CD8 $^{+}$  response to the C-terminal epitopes.

The enhanced immunogenicity of the codon optimized cDNA of hCEA was also tested in transgenic mice using two injections of  $1 \times 10^{10}$  pp of Adenovirus vectors two weeks apart. The CEA-specific immune response was measured by IFN $\gamma$  intracellular staining on pooled PBMC from 4 immunized mice. The immune response to hCEA was detected only in mice immunized with Ad/CEAopt (FIGURE 9). As observed with the DNA plus Ad cohort, induction of CD8 $^{+}$  T-cells was detected with peptide pool D; however, a significant CD8 $^{+}$  response was also noted with peptide pool A. Thus, these results indicate that the codon optimized cDNA of hCEA is more immunogenic and breaks tolerance to hCEA more efficiently than the wild type sequence.

#### EXAMPLE 10

#### Antibodies Detection and Titration.

Sera for antibody titration were obtained by retro-orbital bleeding. ELISA plates (Nunc maxisorp™) were coated with 100 ng/well with CEA protein (highly pure CEA; Fitzgerald Industries International Inc., Concord MA), diluted in coating buffer (50mM NaHCO<sub>3</sub>, pH 9.4) and incubated O/N at 4°C. Plates were then blocked with PBS containing 5% BSA for 1 hr at 37°C. Mouse sera were diluted in PBS 5% BSA (dilution 1/50 to evaluate seroconversion rate; dilutions from 1:10 to 1:31,2150 to evaluate titer). Pre-immune sera were used as background. Diluted sera were incubated O/N at 4°C. Washes were carried out with PBS 1% BSA, 0.05% Tween 20. Secondary antibody (goat anti-mouse, IgG Peroxidase, Sigma) was diluted 1/2000 in PBS, 5% BSA and incubated 2-3 hr at room temp. on a shaker. After washing, plates were developed with 100 µl/well of TMB substrate (Pierce Biotechnology, Inc., Rockford, IL). The reaction was stopped with 25 µl/well of 1M H<sub>2</sub>SO<sub>4</sub> solution and plates were read at 450 nm/620 nm. Anti-CEA serum titers were calculated as the reciprocal limiting dilution of serum producing an absorbance at least 3-fold greater than the absorbance of autologous pre-immune serum at the same dilution.

15

#### EXAMPLE 11

##### Increased Immunogenicity of hCEAopt.

To examine *in vivo* immune responses induced by the wild type and codon optimized CEA expression vectors, C57BL/6 mice were immunized intramuscularly with different doses of Ad5/hCEAopt ranging from 1x10<sup>5</sup> to 1x10<sup>3</sup> pfu. As comparison, groups of 8 to 10 mice were immunized with Ad5/hCEA in doses ranging from 1x10<sup>6</sup> to 1x10<sup>4</sup> pfu. Mice were subjected to two injections three weeks apart. Two weeks after the second immunization, splenocytes were isolated from each mouse. To quantify the IFN $\gamma$  secreting CEA-specific CD8 T-cell precursor frequencies generated by the Adenovirus mediated immunization, the ELISPOT assay for the H-2<sup>b</sup> restricted T-cell epitope CGIQNSVSA (SEQ ID NO:14, see below) was used. Immunization with 1x10<sup>4</sup> pfu elicited a measurable immune response yielding 53 IFN $\gamma$  spot forming cells (SFC, geometric mean value) specific for the CGIQNSVSA epitope (SEQ ID NO:14), whereas injection of 1x10<sup>3</sup> pfu elicited negligible SFC values (FIGURE 3A). The SFC increased to 302 in the group immunized with 1x10<sup>5</sup> pfu of Ad/hCEAopt. In contrast, at least 1x10<sup>5</sup> pfu of Ad5/hCEA were necessary to elicit a significant CD8 T-cell precursor frequencies that increased to 168 SFC in the mouse group immunized with a dose of 1x10<sup>6</sup> pfu. No peptide-specific IFN $\gamma$  SFC were detected in the Ad5 immunized mice (data not shown).

Sera from mice immunized with 1x10<sup>5</sup> pfu of each hCEA Adenovirus vector were tested in ELISA using the purified human CEA protein as substrate (FIGURE 3B). CEA-specific antibody titer in Ad5/hCEAopt immunized mice was detected in all immunized mice and the geometric mean value of the Ab titer was 46,474. In contrast, the Ad5/hCEA immunized group showed an approximately 100 fold

35



lower geometric mean titer of CEA-specific antibody (454). Thus, these results demonstrate that the codon optimized cDNA of CEA is more efficient in eliciting an cellular and humoral immune response.

#### EXAMPLE 12

##### 5 Statistical Analysis.

Where indicated, results were analyzed by the Student t test. A p value < 0.05 was considered significant.

## WHAT IS CLAIMED IS:

1. A synthetic nucleic acid molecule comprising a sequence of nucleotides that encodes a human carcinoembryonic antigen (CEA) protein as set forth in SEQ ID NO:2, the synthetic nucleic acid molecule being codon-optimized for high level expression in a human cell.  
5
2. The synthetic nucleic acid molecule of claim 1 wherein the nucleic acid is DNA.
3. The synthetic nucleic acid molecule of claim 1 wherein the nucleic acid is  
10 mRNA.
4. The synthetic nucleic acid molecule of claim 1 wherein the nucleic acid is cDNA.
5. The synthetic nucleic acid molecule of claim 1 wherein the sequence of nucleotides comprises the sequence of nucleotides set forth in SEQ ID NO:1.  
15
6. A vector comprising the nucleic acid molecule of claim 1.
7. A host cell comprising the vector of claim 6.  
20
8. A process for expressing a human carcinoembryonic antigen (CEA) protein in a recombinant host cell, comprising:
  - (a) introducing a vector comprising the nucleic acid of claim 1 into a suitable host  
25 cell; and,
  - (b) culturing the host cell under conditions which allow expression of said human CEA protein.
9. A method of preventing or treating cancer comprising administering to a  
30 mammal a vaccine vector comprising a synthetic codon-optimized nucleic acid molecule, the nucleic acid molecule comprising a sequence of nucleotides that encodes a human carcinoembryonic antigen (hCEA) protein as set forth in SEQ ID NO:2 or a CEA protein variant as set forth in SEQ ID NO:16.
10. A method according to claim 9 wherein the mammal is human.  
35

11. A method according to claim 9 wherein the vector is an adenovirus vector or a plasmid vector.
12. A method according to claim 9 wherein the vector is an adenoviral vector comprising an adenoviral genome with a deletion in the adenovirus E1 region, and an insert in the adenovirus E1 region, wherein the insert comprises an expression cassette comprising:
- (a) a codon-optimized polynucleotide encoding a human CEA protein or variant thereof; and
  - (b) a promoter operably linked to the polynucleotide.
13. A method according to claim 9 wherein the vector is a plasmid vaccine vector, which comprises a plasmid portion and an expressible cassette comprising
- (a) a codon-optimized polynucleotide encoding a human CEA protein or variant thereof; and
  - (b) a promoter operably linked to the polynucleotide.
14. An adenovirus vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising:
- (a) a codon-optimized polynucleotide encoding a human CEA protein or variant thereof; and
  - (b) a promoter operably linked to the polynucleotide.
15. An adenovirus vector according to claim 14 which is an Ad 5 vector.
16. An adenovirus vector according to claim 14 which is an Ad 6 vector.
17. An adenovirus vector according to claim 14 which is an Ad 24 vector.
18. A vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising:
- (a) a codon-optimized polynucleotide encoding a human CEA protein or variant thereof; and
  - (b) a promoter operably linked to the polynucleotide.

19. A method of protecting a mammal from cancer comprising:
- (a) introducing into the mammal a first vector comprising:
- (i) a codon-optimized polynucleotide encoding a human carcinoembryonic antigen (CEA) protein or variant thereof; and
- 5 (ii) a promoter operably linked to the polynucleotide;
- (b) allowing a predetermined amount of time to pass; and
- (c) introducing into the mammal a second vector comprising:
- (i) a codon-optimized polynucleotide encoding a human CEA protein or variant thereof; and
- 10 (ii) a promoter operably linked to the polynucleotide.
20. A method according to claim 19 wherein the first vector is a plasmid and the second vector is an adenovirus vector.
- 15 21. A method according to claim 19 wherein the first vector is an adenovirus vector and the second vector is a plasmid.
22. A method of treating a mammal suffering from a colorectal carcinoma comprising:
- 20 (a) introducing into the mammal a first vector comprising:
- (i) a codon-optimized polynucleotide encoding a human CEA protein or variant thereof; and
- (ii) a promoter operably linked to the polynucleotide;
- (b) allowing a predetermined amount of time to pass; and
- 25 (c) introducing into the mammal a second vector comprising:
- (i) a codon-optimized polynucleotide encoding a human CEA protein or variant thereof; and
- (ii) a promoter operably linked to the polynucleotide.
- 30 23. A method according to claim 22 wherein the first vector is a plasmid and the second vector is an adenovirus vector.
24. A method according to claim 22 wherein the first vector is an adenovirus vector and the second vector is a plasmid.
- 35

25. A synthetic nucleic acid molecule comprising a sequence of nucleotides that encodes a human carcinoembryonic antigen (CEA) protein variant as set forth in SEQ ID NO:16, the synthetic nucleic acid molecule being codon-optimized for high level expression in a human cell.
- 5                    26. The synthetic nucleic acid molecule of claim 25 wherein the sequence of nucleotides comprises the sequence of nucleotides set forth in SEQ ID NO:15.
27. A vector comprising the nucleic acid molecule of claim 25.
- 10                   28. A host cell comprising the vector of claim 27.

## FIGURE 1. Human Codon-Optimized CEA Sequence

1	MetGluSerProSerAlaProProHisArgTrpCysIleProTrpGlnArgLeuLeuLeu	20
1	ATGGAGTCTCCCTCGCCCCCTCCACAGATGGTGCATCCCTGGCAGAGGCTCCTGCTC	60
	.....AGC...AGC.....C.....C.C.....C.C..G....G	
21	ThrAlaSerLeuLeuThrPheTrpAsnProProThrThrAlaLysLeuThrIleGluSer	40
61	ACAGCCTCACTTCTAACCTTCTGGAACCCGCCACCACTGCCAAGCTCACTATTGAATCC	120
	..C....AGC..G..G.....C.....C.....G..C..C..GAG.	
41	ThrProPheAsnValAlaGluGlyLysGluValLeuLeuLeuValHisAsnLeuProGln	60
121	ACGCCGTTCATGTTCGAGAGGGGAAGGAGGTGCTTCTACTTGTCACAATCTGCCCCAG	180
	..C..C.....C..G..C.....C.....G..G..G..C.....C.....	
61	HisLeuPheGlyTyrSerTrpTyrLysGlyGluArgValAspGlyAsnArgGlnIleIle	80
181	CATCTTTTGGCTACAGCTGGTACAAAGGTGAAAGAGTGGATGGCAACCGTCAAATTATA	240
	..C..G..C'.....G..C..GC.C.....C.....C..G..C..C	
81	GlyTyrValIleGlyThrGlnGlnAlaThrProGlyProAlaTyrSerGlyArgGluIle	100
241	GGATATGTAATAGGAAGTCAACAAGCTACCCAGGGCCCGCATACAGTGGTCGAGAGATA	300
	..C..C..G..C..C..C..G..G..C.....C..C.....C.....C..C.....C	
101	IleTyrProAsnAlaSerLeuLeuIleGlnAsnIleIleGlnAsnAspThrGlyPheTyr	120
301	ATATACCCCAATGCATCCCTGCTGATCCAGAACATCATCCAGAATGACACAGGATTCTAC	360
	..C.....C..CAG.....C.....C.....C.....C.....	
121	ThrLeuHisValIleLysSerAspLeuValAsnGluGluAlaThrGlyGlnPheArgVal	140
361	ACCCTACACGTCATAAAGTCAGATCTTGTGAATGAAGAAGCAACTGGCCAGTTCCGGGTA	420
	.....G.....G..C...AGC..C..G.....C..G..G..C..C.....C..G	
141	TyrProGluLeuProLysProSerIleSerSerAsnAsnSerLysProValGluAspLys	160
421	TACCCGGAGCTGCCCAAGCCCTCCATCTCCAGCAACAACCTCCAAACCCGTGGAGGACAAG	480
	.....C.....AG....AG.....AG...G.....	
161	AspAlaValAlaPheThrCysGluProGluThrGlnAspAlaThrTyrLeuTrpTrpVal	180
481	GATGCTGTGGCCTTCACCTGTGAACCTGAGACTCAGGACGCAACCTACCTGTGGTGGGTA	540
	..C..C.....C..G..C.....C.....C.....C.....G	
181	AsnAsnGlnSerLeuProValSerProArgLeuGlnLeuSerAsnGlyAsnArgThrLeu	200
541	AACAATCAGAGCCTCCCGGTCAGTCCCAGGCTGCAGCTGTCCAATGGCAACAGGACCCTC	600
	.....C.....G..C..G..C...C.C.....AG...C.....C.C.....G	
201	ThrLeuPheAsnValThrArgAsnAspThrAlaSerTyrLysCysGluThrGlnAsnPro	220
601	ACTCTATTCAATGTACAGAAATGACACAGCAAGCTACAAATGTGAAACCCAGAACCCA	660
	..C..G.....C..G..CC.C..C.....C..C.....G..C..G.....C	
221	ValSerAlaArgArgSerAspSerValIleLeuAsnValLeuTyrGlyProAspAlaPro	240
661	GTGAGTGCCAGGCGCAGTGATTCACTCATCCTGAATGTCCTCTATGGCCCGGATGCCCCC	720
	.....C...C.C.....C..CAGC..G.....C..G..G..C.....C..C.....	
241	ThrIleSerProLeuAsnThrSerTyrArgSerGlyGluAsnLeuAsnLeuSerCysHis	260
721	ACCATTTCCCTCTAAACACATCTTACAGATCAGGGGAAAATCTGAACCTCTCCTGCCAC	780
	.....CAG...C..G.....CAGC..C.CAGC..C..G..C.....GAG.....	
261	AlaAlaSerAsnProProAlaGlnTyrSerTrpPheValAsnGlyThrPheGlnGlnSer	280
781	GCAGCCTCTAACCCACCTGCACAGTACTCTTGGTTGTCAATGGGACTTTCCAGCAATCC	840
	..C...AGC.....C..C.....AGC.....C..G..C..C..C.....GAG.	
281	ThrGlnGluLeuPheIleProAsnIleThrValAsnAsnSerGlySerTyrThrCysGln	300

841 ACCCAAGAGCTCTTTATCCCCAACATCACTGTGAATAATAGTGGATCCTATACGTGCCAA 900  
.....G.....G..C.....C.....C..C..C..CAG...C..C.....G

301 AlaHisAsnSerAspThrGlyLeuAsnArgThrThrValThrThrIleThrValTyrAla 320  
901 GCCCATAACTCAGACACTGGCCTCAATAGGACCACAGTCACGACGATCACAGTCATGCA 960  
.....C...AGC.....C.....G..CC.C.....C..G..C..C.....C..G..C..C

321 GluProProLysProPheIleThrSerAsnAsnSerAsnProValGluAspGluAspAla 340  
961 GAGCCACCCAAACCTTTCATCACCAGCAACAACCTCCAACCCCGTGGAGGATGAGGATGCT 1020  
.....C.....G.....AG.....C.....C..C

341 ValAlaLeuThrCysGluProGluIleGlnAsnThrThrTyrLeuTrpTrpValAsnAsn 360  
1021 GTAGCCTTAACCTGTGAACCTGAGATTGAGAACACAACCTACCTGTGGTGGGTAAATAAT 1080  
..G...C.G.....C..G..C.....C.....C.....G..C..C

361 GlnSerLeuProValSerProArgLeuGlnLeuSerAsnAspAsnArgThrLeuThrLeu 380  
1081 CAGAGCCTCCCGGTCAGTCCAGGCTGCAGCTGTCCAATGACAACAGGACCCCTCACTCTA 1140  
.....G..C..G..C...C.C.....AG...C.....C.C.....G..C..G

381 LeuSerValThrArgAsnAspValGlyProTyrGluCysGlyIleGlnAsnGluLeuSer 400  
1141 CTCAGTGTGACAGGAATGATGTAGGACCTATGAGTGTGGAATCCAGAACGAATTAAGT 1200  
..G..C..G..CC.C..C..C..G..C.....C.....C..C.....GC.G..C

401 ValAspHisSerAspProValIleLeuAsnValLeuTyrGlyProAspAspProThrIle 420  
1201 GTTGACCACAGCGACCCAGTCATCCTGAATGTCTCTATGGCCCGACGACCCCACTATT 1260  
..G.....C.....C..G.....C..G..G..C.....C.....C

421 SerProSerTyrThrTyrTyrArgProGlyValAsnLeuSerLeuSerCysHisAlaAla 440  
1261 TCCCCCTCATACCTATTACCGTCCAGGGGTGAACCTCAGCCTCTCTGCCATGCAAGCC 1320  
AG.....AGC.....C.....C..C..C.....G.....GAG.....C..C...

441 SerAsnProProAlaGlnTyrSerTrpLeuIleAspGlyAsnIleGlnGlnHisThrGln 460  
1321 TCTAACCACCTGCACAGTATTCTTGGCTGATTGATGGGAACATCCAGCAACACACACAA 1380  
AGC.....C..C..C.....CAGC.....C..C..C.....G.....C..G

461 GluLeuPheIleSerAsnIleThrGluLysAsnSerGlyLeuTyrThrCysGlnAlaAsn 480  
1381 GAGCTCTTTATCTCCAACATCACTGAGAAGAACAGCGGACTCTATACCTGCCAGGCCAAT 1440  
.....G..C...AG.....C.....C..G..C.....C

481 AsnSerAlaSerGlyHisSerArgThrThrValLysThrIleThrValSerAlaGluLeu 500  
1441 AACTCAGCCAGTGGCCACAGCAGGACTACAGTCAAGACAATCACAGTCTCTGCCGAGCTG 1500  
...AGC.....C.....C.C..C..C..G.....C.....C..GAGC..C.....

501 ProLysProSerIleSerSerAsnAsnSerLysProValGluAspLysAspAlaValAla 520  
1501 CCCAAGCCCTCCATCTCCAGCAACAACCTCAAACCCGTCGAGGACCAAGGATGCTGTGGCC 1560  
.....AG....AG.....AG...G.....C..C.....

521 PheThrCysGluProGluAlaGlnAsnThrThrTyrLeuTrpTrpValAsnGlyGlnSer 540  
1561 TTCACCTGTGAACCTGAGGCTCAGAACACAACCTACCTGTGGTGGGTAAATGGTCAGAGC 1620  
.....C..G..C.....C.....C.....G..C..C.....

541 LeuProValSerProArgLeuGlnLeuSerAsnGlyAsnArgThrLeuThrLeuPheAsn 560  
1621 CTCCAGTCAGTCCAGGCTGCAGCTGTCCAATGGCAACAGGACCCCTACTCTATCAAT 1680  
..G..C..G..C...C.C.....AG...C.....C.C.....G..C..G.....C

561 ValThrArgAsnAspAlaArgAlaTyrValCysGlyIleGlnAsnSerValSerAlaAsn 580  
1681 GTCACAAGAAATGACGCAAGAGCCTATGTATGTGGAATCCAGAACTCAGTGAGTGCAAAC 1740  
..G..CC.C..C.....CC.C.....C..G..C..C.....AGC.....C..C...

581 ArgSerAspProValThrLeuAspValLeuTyrGlyProAspThrProIleIleSerPro 600  
1741 CGCAGTGACCCAGTCACCCTGGATGTCTCTATGGGCCGGACACCCCATCATTTCCCCC 1800  
.....C.....C..G.....C..G..G..C..C..C.....CAG....

601 ProAspSerSerTyrLeuSerGlyAlaAsnLeuAsnLeuSerCysHisSerAlaSerAsn 620  
1801 CCAGACTCGTCTTACCTTTCCGGAGCGAACCTCAACCTCTCTGCCACTCGGCCTCTAAC 1860  
..C...AGCAGC.....GAGC..C..C.....GAG.....AGC...AGC...

621 ProSerProGlnTyrSerTrpArgIleAsnGlyIleProGlnGlnHisThrGlnValLeu 640  
1861 CCATCCCCGAGTATTCTTGGCGTATCAATGGGATACCGCAGCAACACACACAAGTTCTC 1920  
..CAG...C.....CAGC.....C.....C..C..C.....G.....C..G..G..G

641 PheIleAlaLysIleThrProAsnAsnAsnGlyThrTyrAlaCysPheValSerAsnLeu 660  
1921 TTTATCGCCAAAATCACGCCAAATAATAACGGGACCTATGCCTGTTTGTCTCTAACTTG 1980  
..C.....G.....C..C..C..C.....C.....C.....C..GAGC...C..

661 AlaThrGlyArgAsnAsnSerIleValLysSerIleThrValSerAlaSerGlyThrSer 680  
1981 GCTACTGGCCGCAATAATTCCATAGTCAAGAGCATCACAGTCTCTGCATCTGGAAGTTCT 2040  
..C..C.....C..CAG...C..G.....C..GAGC..CAGC..C..CAGC

681 ProGlyLeuSerAlaGlyAlaThrValGlyIleMetIleGlyValLeuValGlyValAla 700  
2041 CCTGGTCTCTCAGCTGGGGCCACTGTCGGCATCATGATTGGAGTGCTGGTTGGGGTTGCT 2100  
..C..C..GAGC..C..C.....C..G.....C..C.....G..C..G..C

701 LeuIleEnd 703 (SEQ ID NO:2)  
2101 CTGATATAG 2109 (SEQ ID NO:3)  
.....C.GA (SEQ ID NO:1)



FIGURE 2A. Expression of hCEA in Mice Injected with MRKAd5 Vectors





FIGURE 2B. Expression of hCEA in Mice Injected with pV1J Vectors






FIGURE 3B. Humoral Immune Response to Human CEA







FIGURE 4A. Comparison of Immunization Regimens Used for C57BL/6 Mice





**FIGURE 4B. Comparison of Immunization Regimens Used for BALB/c Mice**

[illegible]





**FIGURE 6A. Immunoresponsive Peptides of hCEA in Immunized C57BL/6 Mice**

**FIGURE 6B. Immunoresponsive Peptides of hCEA in Immunized BALB/c Mice**

**FIGURE 7. Sequence of Epitope-Containing Peptides for CEA****A. C57BL/6**

<b>Pool</b>	<b>Peptide</b>	<b>Position</b>	<b>Sequence</b>	<b>SEQ ID NO.</b>	<b>CD8</b>	<b>CD4</b>
C	CEA-107	425-439	TYRPGVNLSLSCHA	4	0.02	0.14
D	CEA-133	539-543	NTTYLWWVNGQSLPV	5	0.01	0.04
D	CEA-143	569-583	YVCGIQNSVSANRSD	6	0.64	0.01
D	CEA-155	617-631	SASNPSQYSWRING	7	0.03	0.06
	DMSO				0.01	0.01

**B. BALB/c**

<b>Pool</b>	<b>Peptide</b>	<b>Position</b>	<b>Sequence</b>	<b>SEQ ID NO.</b>	<b>CD8</b>	<b>CD4</b>
B	CEA-58	229-243	VILNVLYGPDAPTIS	8	0.51	0.01
C	CEA-98	389-403	GPYECGIQNELSVDH	9	0.01	0.14
C	CEA-106	421-435	SPSYTYRPGVNLSL	10	0.01	0.16
D	CEA-156	621-635	PSPQYSWRINGIPQQ	11	0.01	0.12
D	CEA-167	665-679	NNSIVKSITVSASGT	12	0.13	0.03
	DMSO				0.01	0.01

**FIGURE 8. IFN $\gamma$ -ELISPOT analysis of immunized CEA.tg mice<sup>a</sup>**

<b>Immunogen</b>	<b>pool A</b>	<b>pool B</b>	<b>pool C</b>	<b>pool D</b>	<b>CD8</b>	<b>DMSO</b>
hCEAopt	34	3	9	464	492	2
hCEA	0	2	3	9	1	0

<sup>a</sup>SFC/10<sup>6</sup> splenocytes

**FIGURE 9. IFN $\gamma$  -Intracellular Staining of Immunized CEA.tg Mice**

immunogen peptides	hCEA		hCEAopt	
	CD8	CD4	CD8	CD4
Pool A	0	0	0.89	0.05
Pool B	0.01	0	0.02	0.03
Pool C	0	0	0	0
Pool D	0	0.06	0.2	0.02
DMSO	0.02	0	0.02	0

**FIGURE 10A. Nucleotide Sequence of Human CEA-ΔAD**

```

1   ATGGAGAGCC CCAGCGCCCC CCCCCACCGC TGGTGCATCC CCTGGCAGCG
   CCTGCTGCTG ACCGCCAGCC TGCTGACCTT CTGGAACCCC CCCACCACCG
101  CCAAGCTGAC CATCGAGAGC ACCCCCTTCA ACGTGGCCGA GGGCAAGGAG
   GTGCTGCTGC TGGTGCACAA CCTGCCCCAG CACCTGTTCG GCTACAGCTG
201  GTACAAGGGC GAGCGCGTGG ACGGCAACCG CCAGATCATC GGCTACGTGA
   TCGGCACCCA GCAGGCCACC CCCGGCCCCG CCTACAGCGG CCGCGAGATC
301  ATCTACCCCA ACGCCAGCCT GCTGATCCAG AACATCATCC AGAACGACAC
   CGGCTTCTAC ACCCTGCACG TGATCAAGAG CGACCTGGTG AACGAGGAGG
401  CCACCGGCCA GTTCCGCGTG TACCCCGAGC TGCCCAAGCC CAGCATCAGC
   AGCAACAACA GCAAGCCCGT GGAGGACAAG GACGCCGTGG CCTTCACCTG
501  CGAGCCCGAG ACCCAGGACG CCACCTACCT GTGGTGGGTG AACAAACCAGA
   GCCTGCCCCG GAGCCCCCGC CTGCAGCTGA GCAACGGCAA CCGCACCTTG
601  ACCCTGTTCA ACGTGACCCG CAACGACACC GCCAGCTACA AGTGCAGAGC
   CCAGAACCCC GTGAGCGCCC GCCGCAGCGA CAGCGTGATC CTGACCGTGC
701  TGTACGGCCC CGACGCCCCC ACCATCAGCC CCCTGAACAC CAGCTACCGC
   AGCGGCGAGA ACCTGAACCT GAGCTGCCAC GCCGCCAGCA ACCCCCCCGC
801  CCAGTACAGC TGGTTCGTGA ACGGCACCTT CCAGCAGAGC ACCCAGGAGC
   TGTTCATCCC CAACATCACC GTGAACAACA GCGGCAGCTA CACCTGCCAG
901  GCCCACAACA GCGACACCGG CCTGAACCCG ACCACCGTGA CCACCATCAC
   CGTGTACGCC GAGCCCCCCA AGCCCTTCAT CACCAGCAAC AACAGCAACC
1001 CCGTGGAGGA CGAGGACGCC GTGGCCCTGA CCTGCGAGCC CGAGATCCAG
   AACACCACCT ACCTGTGGTG GGTGAACAAC CAGAGCCTGC CCGTGAGCCC
1101 CCGCCTGCAG CTGAGCAACG ACAACCGCAC CCTGACCCTG CTGAGCGTGA
   CCCGCAACGA CGTGGGCCCC TACGAGTGCG GCATCCAGAA CGAGCTGAGC
1201 GTGGACCACA GCGACCCCGT GATCCTGAAC GTGCTGTACG GCCCCGACGA
   CCCCACCATC AGCCCCAGCT ACACCTACTA CCGCCCCGGC GTGAACCTGA
1301 GCCTGAGCTG CCACGCCGCC AGCAACCCCC CCGCCCAGTA CAGCTGGCTG
   ATCGACGGCA ACATCCAGCA GCACACCCAG GAGCTGTTCA TCAGCAACAT
1401 CACCGAGAAG AACAGCGGCC TGTACACCTG CCAGGCCAAC AACAGCGCCA
   GCGGCCACAG CCGCACCAAC GTGAAGACCA TCACCGTGAG CGCCGAGCTG
1501 CCAAGCCCA GCATCAGCAG CAACAACAGC AAGCCCGTGG AGGACAAGGA
   CGCCGTGGCC TTCACCTGCG AGCCCGAGGC CCAGAACACC ACCTACCTGT
1601 GGTGGGTGAA CGGCCAGAGC CTGCCCCTGA GCCCCGCGCT GCAGCTGAGC
   AACGGCAACC GCACCTGAC CCTGTTCAAC GTGACCCGCA ACGACGCCCG
1701 CGCCTACGTG TGCGGCATCC AGAACAGCGT GAGCGCCAAC CGCAGCGACC
   CCGTGACCTT GGACGTGCTG TACGGCCCCG ACACCCCAT CATCAGCCCC
1801 CCCGACAGCA GCTACCTGAG CGGCGCCAAC CTGAACCTGA GCTGCCACAG
   CGCCAGCAAC CCCAGCCCCC AGTACAGCTG GCGCATCAAC GGCATCCCCC
1901 AGCAGCACAC CCAGGTGCTG TTCATCGCCA AGATACCCCC CAACAACAAC
   GGCACCTACG CCTGCTTCGT GAGCAACCTG GCCACCGGCC GCAACAACAG
2001 CATCGTGAAG AGCATCACCG TGAGCGCCAG CGGC (SEQ ID NO:15)

```

**FIGURE 10B. Amino Acid Sequence of Human CEA-ΔAD**

```
1  MESPSAPPHR WCIPWQRLLL TASLLTFWNP PTTAKLTIES TPFNVAEGKE
51  VLLLVDHNLPO HLFYGSWYKG ERVDGNRQII GYVIGTQQAT PGPAYSGREI
101 IYPNASLLIQ NIIQNDTGFI TLHVIKSDLV NEEATGQFRV YPELPKPSIS
151 SNNSKPVEDK DAVAFTEPE TQDATYLWWV NNQSLPVSPR LQLSNGNRTL
201 TLFNVTRNDT ASYKCEQNP VSARRSDSVI LNVLYGPDAP TISPLNTSYR
251 SGENLNLSCH AASNPPAQYS WFNVTGTFQS TQELFIPNIT VNNSGSYTCQ
301 AHNSDTGLNR TTVTTITVYA EPPKPFITSN NSNPVEDEDA VALTCEPEIQ
351 NTTYLWVWNN QSLPVSPRLQ LSNDNRTLTL LSVTRNDVGP YECGIQNELS
401 VDHSDPVILN VLYGPDDPTI SPSYTYRPG VNLSLSCHAA SNPPAQYSWL
451 IDGNIQQHTQ ELFISNITEK NSGLYTCQAN NSASGHSRTT VKTITVSAEL
501 PKPSISSNNS KPVEDKDAVA FTCEPEAQNT TYLWWVNGQS LPVSPRLQLS
551 NGNRTLTLFN VTRNDARAYV CGIQNSVSAN RSDPVTLDVL YGPDTPILSP
601 PDSSYLSGAN LNLSCHSASN PSPQYSWRIN GIPQOHTQVL FIAKITPNNN
651 GTYACFVSNL ATGRNNSIVK SITVSASG (SEQ ID NO:16)
```

## SEQUENCE LISTING

<110> Istituto Di Ricerche Di Biologia Molecolar P. Angeletti S.P.A.

Lamonica, Nicola

Mennuni, Carmela

Savino, Rocco

Lahm, Armin

<120> SYNTHETIC GENE ENCODING HUMAN  
CARCINOEMBRYONIC ANTIGEN AND USES THEREOF

<130> ITR0044Y

<150> 60/467,971

<151> 2003-05-05

<150> Unknown

<151> 2004-02-11

<160> 16

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2109

<212> DNA

<213> Artificial Sequence

<220>

<223> hCEAopt

<400> 1

```

atggagagcc ccagcgcccc cccccaccgc tgggtgcatcc cctggcagcg cctgctgctg 60
accgccagcc tgctgacctt ctggaacccc cccaccaccg ccaagctgac catcgagagc 120
accccccttca acgtggccga gggcaaggag gtgctgctgc tgggtgcacaa cctgccccag 180
cacctgttcg gctacagctg gtacaagggc gagcgcgctg acggcaaccg ccagatcatc 240
ggctacgtga tcggcaccca gcaggccacc cccggccccg cctacagcgg ccgcgagatc 300
atctacccca acgccagcct gctgatccag aacatcatcc agaacgacac cggcttctac 360
accctgcacg tgatcaagag cgacctggtg aacgaggagg ccaccggcca gttccgcgtg 420
taccgagcgc tgcccaagcc cagcatcagc agcaacaaca gcaagcccggt ggaggacaag 480
gacgccgtgg ccttcacctg cgagcccagc acccaggacg ccacctacct gtggtgggtg 540
aacaaccaga gcctgcccgt gagccccgc ctgcagctga gcaacggcaa ccgcaccctg 600
accctgttca acgtgacccg caacgacacc gccagctaca agtgcgagac ccagaacccc 660
gtgagcgccc gccgcagcga cagcgtgatc ctgaacgtgc tgtacggccc cgacgcccc 720
accatcagcc ccctgaacac cagctaccgc agcggcgaga acctgaacct gagctgccac 780
gccgcagca accccccgc ccagtacagc tggttcgtga acggcacctt ccagcagagc 840
acccaggagc tgttcatccc caacatcacc gtgaacaaca gcggcagcta cacctgccag 900
gcccacaaca gcgacaccgg cctgaaccgc accaccgtga ccaccatcac cgtgtacgcc 960
gagccccca agcccttcat caccagcaac aacagcaacc ccgtggagga cgaggacgcc 1020
gtggccctga cctgcgagcc cgagatccag aacaccacct acctgtggtg ggtgaacaac 1080
cagagcctgc ccgtgagccc ccgcctgcag ctgagcaacg acaaccgcac cctgaccctg 1140
ctgagcgtga cccgaacga cgtgggcccc tacgagtgcg gcatccagaa cgagctgagc 1200
gtggaccaca gcgaccccggt gatcctgaac gtgctgtacg gccccgacga cccaccatc 1260

```



```

agccccagct acacctacta ccgccccggc gtgaacctga gcctgagctg ccacgcccgc 1320
agcaaccccc ccgcccagta cagctggctg atcgacggca acatccagca gcacaccag 1380
gagctgttca tcagcaacat caccgagaag aacagcggcc tgtacacctg ccaggccaac 1440
aacagcgcca gcggccacag ccgcaccacc gtgaagacca tcaccgtgag cgccgagctg 1500
cccaagcccc gcatcagcag caacaacagc aagcccgtgg aggacaagga cgccgtggcc 1560
ttcacctgcg agcccagggc ccagaacacc acctacctgt ggtgggtgaa cggccagagc 1620
ctgcccgtga gccccgcct gcagctgagc aacggcaacc gcaccctgac cctgttcaac 1680
gtgacccgca acgacgccc cgcctacgtg tgcggcatcc agaacagcgt gagcgccaac 1740
cgagcgcacc ccgtgaccct ggacgtgctg tacggccccg acacccccat catcagcccc 1800
cccagacagca gctacctgag cggcgccaac ctgaacctga gctgccacag cgccagcaac 1860
cccagcccc agtacagctg gcgcatcaac ggcaccccc agcagcacac ccaggtgctg 1920
ttcatcgcca agatcacccc caacaacaac ggcacctacg cctgttcgt gagcaacctg 1980
gccaccggcc gcaacaacag catcgtgaag agcatcaccg tgagcgccag cggcaccagc 2040
cccgccctga gcgcggcgc caccgtgggc atcatgatcg gcgtgctggt gggcggtggc 2100
ctgatctga 2109

```

&lt;210&gt; 2

&lt;211&gt; 702

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Met Glu Ser Pro Ser Ala Pro Pro His Arg Trp Cys Ile Pro Trp Gln
1 5 10 15
Arg Leu Leu Leu Thr Ala Ser Leu Leu Thr Phe Trp Asn Pro Pro Thr
20 25 30
Thr Ala Lys Leu Thr Ile Glu Ser Thr Pro Phe Asn Val Ala Glu Gly
35 40 45
Lys Glu Val Leu Leu Leu Val His Asn Leu Pro Gln His Leu Phe Gly
50 55 60
Tyr Ser Trp Tyr Lys Gly Glu Arg Val Asp Gly Asn Arg Gln Ile Ile
65 70 75 80
Gly Tyr Val Ile Gly Thr Gln Gln Ala Thr Pro Gly Pro Ala Tyr Ser
85 90 95
Gly Arg Glu Ile Ile Tyr Pro Asn Ala Ser Leu Leu Ile Gln Asn Ile
100 105 110
Ile Gln Asn Asp Thr Gly Phe Tyr Thr Leu His Val Ile Lys Ser Asp
115 120 125
Leu Val Asn Glu Glu Ala Thr Gly Gln Phe Arg Val Tyr Pro Glu Leu
130 135 140
Pro Lys Pro Ser Ile Ser Ser Asn Asn Ser Lys Pro Val Glu Asp Lys
145 150 155 160
Asp Ala Val Ala Phe Thr Cys Glu Pro Glu Thr Gln Asp Ala Thr Tyr
165 170 175
Leu Trp Trp Val Asn Asn Gln Ser Leu Pro Val Ser Pro Arg Leu Gln
180 185 190
Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Phe Asn Val Thr Arg Asn
195 200 205
Asp Thr Ala Ser Tyr Lys Cys Glu Thr Gln Asn Pro Val Ser Ala Arg
210 215 220
Arg Ser Asp Ser Val Ile Leu Asn Val Leu Tyr Gly Pro Asp Ala Pro
225 230 235 240
Thr Ile Ser Pro Leu Asn Thr Ser Tyr Arg Ser Gly Glu Asn Leu Asn
245 250 255
Leu Ser Cys His Ala Ala Ser Asn Pro Pro Ala Gln Tyr Ser Trp Phe

```

				260													270
Val	Asn	Gly	Thr	Phe	Gln	Gln	Ser	Thr	Gln	Glu	Leu	Phe	Ile	Pro	Asn		
		275					280					285					
Ile	Thr	Val	Asn	Asn	Ser	Gly	Ser	Tyr	Thr	Cys	Gln	Ala	His	Asn	Ser		
	290					295					300						
Asp	Thr	Gly	Leu	Asn	Arg	Thr	Thr	Val	Thr	Thr	Ile	Thr	Val	Tyr	Ala		
305					310					315					320		
Glu	Pro	Pro	Lys	Pro	Phe	Ile	Thr	Ser	Asn	Asn	Ser	Asn	Pro	Val	Glu		
			325						330					335			
Asp	Glu	Asp	Ala	Val	Ala	Leu	Thr	Cys	Glu	Pro	Glu	Ile	Gln	Asn	Thr		
			340					345					350				
Thr	Tyr	Leu	Trp	Trp	Val	Asn	Asn	Gln	Ser	Leu	Pro	Val	Ser	Pro	Arg		
		355				360						365					
Leu	Gln	Leu	Ser	Asn	Asp	Asn	Arg	Thr	Leu	Thr	Leu	Leu	Ser	Val	Thr		
	370					375					380						
Arg	Asn	Asp	Val	Gly	Pro	Tyr	Glu	Cys	Gly	Ile	Gln	Asn	Glu	Leu	Ser		
385					390					395					400		
Val	Asp	His	Ser	Asp	Pro	Val	Ile	Leu	Asn	Val	Leu	Tyr	Gly	Pro	Asp		
				405				410					415				
Asp	Pro	Thr	Ile	Ser	Pro	Ser	Tyr	Thr	Tyr	Tyr	Arg	Pro	Gly	Val	Asn		
			420					425					430				
Leu	Ser	Leu	Ser	Cys	His	Ala	Ala	Ser	Asn	Pro	Pro	Ala	Gln	Tyr	Ser		
		435				440						445					
Trp	Leu	Ile	Asp	Gly	Asn	Ile	Gln	Gln	His	Thr	Gln	Glu	Leu	Phe	Ile		
	450					455					460						
Ser	Asn	Ile	Thr	Glu	Lys	Asn	Ser	Gly	Leu	Tyr	Thr	Cys	Gln	Ala	Asn		
465					470					475					480		
Asn	Ser	Ala	Ser	Gly	His	Ser	Arg	Thr	Thr	Val	Lys	Thr	Ile	Thr	Val		
				485				490					495				
Ser	Ala	Glu	Leu	Pro	Lys	Pro	Ser	Ile	Ser	Ser	Asn	Asn	Ser	Lys	Pro		
			500					505					510				
Val	Glu	Asp	Lys	Asp	Ala	Val	Ala	Phe	Thr	Cys	Glu	Pro	Glu	Ala	Gln		
		515				520						525					
Asn	Thr	Thr	Tyr	Leu	Trp	Trp	Val	Asn	Gly	Gln	Ser	Leu	Pro	Val	Ser		
	530					535					540						
Pro	Arg	Leu	Gln	Leu	Ser	Asn	Gly	Asn	Arg	Thr	Leu	Thr	Leu	Phe	Asn		
545					550					555					560		
Val	Thr	Arg	Asn	Asp	Ala	Arg	Ala	Tyr	Val	Cys	Gly	Ile	Gln	Asn	Ser		
				565				570					575				
Val	Ser	Ala	Asn	Arg	Ser	Asp	Pro	Val	Thr	Leu	Asp	Val	Leu	Tyr	Gly		
			580					585					5				

<210> 3  
<211> 2109  
<212> DNA  
<213> Homo sapiens

<400> 3  
atggagtctc cctcggcccc tccccacaga tgggtgcatcc cctggcagag gctcctgctc 60  
acagcctcac ttctaacctt ctggaacccg cccaccactg ccaagctcac tattgaatcc 120  
acgccgttca atgtcgcaga ggggaaggag gtgcttctac ttgtccacaa tctgccccag 180  
catctttttg gctacagctg gtacaaagggt gaaagagtgg atggcaaccg tcaaattata 240  
ggatatgtaa taggaactca acaagctacc ccagggcccg catacagtgg tcgagagata 300  
atatacccca atgcatccct gctgatccag aacatcatcc agaatgacac aggattctac 360  
accctacacg tcataaagtc agatcttgtg aatgaagaag caactggcca gttccgggta 420  
tacccgagagc tgccaagcc ctccatctcc agcaacaact ccaaacccgt ggaggacaag 480  
gatgctgtgg ccttcacctg tgaacctgag actcaggacg caacctacct gtggtgggta 540  
aacaatcaga gctcccgggt cagtcccagg ctgcagctgt ccaatggcaa caggaccctc 600  
actctattca atgtcacaa aaatgacaca gcaagctaca aatgtgaaac ccagaaccca 660  
gtgagtgcc a ggcgcagtga ttcagtcctc ctgaatgtcc tctatggccc ggatgcccc 720  
accatttccc ctctaaacac atcttacaga tcaggggaaa atctgaacct ctctgcccac 780  
gcagcctcta acccacctgc acagtactct tggtttgtca atgggacttt ccagcaatcc 840  
acccaagagc tctttatccc caacatcact gtgaataata gtggatccta tacgtgcca 900  
gcccataact cagacactgg cctcaatagg accacagtca cgacgatcac agtctatgca 960  
gagccacca aacccttcat caccagcaac aactccaacc ccgtggagga tgaggatgct 1020  
gtagccttaa cctgtgaacc tgagattcag aacacaacct acctgtggtg ggtaaataat 1080  
cagagcctcc cggtcagtcc caggctgcag ctgtccaatg acaacaggac cctcactcta 1140  
ctcagtgtca caaggaatga tgtaggaccc tatgagtgtg gaatccagaa cgaattaagt 1200  
gttgaccaca gcgacccagt catcctgaat gtcctctatg gccagacga cccaccatt 1260  
tcccctcat acacctatta ccgtccagggt gtgaacctca gcctctctg ccatgcagcc 1320  
tctaaccac ctgcacagta ttcttggctg attgatggga acatccagca acacacacaa 1380  
gagctcttta tctccaacat cactgagaag aacagcggac tctatacctg ccaggccaat 1440  
aactcagcca gtggccacag caggactaca gtcaagacaa tcacagtctc tgcggagctg 1500  
cccaagccct ccatctccag caacaactcc aaaccctgg aggacaagga tgctgtggcc 1560  
ttcactgtg aacctgaggg tcagaacaca acctacctgt ggtgggtaaa tggtcagagc 1620  
ctcccagtca gtcccaggct gcagctgtcc aatggcaaca ggaccctcac tctattcaat 1680  
gtcacaagaa atgacgcaag agcctatgta tgtggaatcc agaactcagt gactgcaaac 1740  
cgcagtgaac cagtcaccct ggatgtcctc tatgggcccg acaccccat catttcccc 1800  
ccagactcgt cttacctttc gggagcgaac ctcaacctct cctgccactc ggcctctaac 1860  
ccatccccgc agtattcttg gcgtatcaat gggataccgc agcaacacac acaagtctc 1920  
tttatcgcca aaatcacgcc aaataataac gggacctatg cctgttttgt ctctaacttg 1980  
gctactggcc gcaataattc catagtcaag agcatcacag tctctgcac tggaaactct 2040  
cctggtctct cagctggggc cactgtcggc atcatgattg gactgctggt tggggttgct 2100  
ctgatatag 2109

<210> 4  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> peptide

<400> 4  
Thr Tyr Tyr Arg Pro Gly Val Asn Leu Ser Leu Ser Cys His Ala

1 5 10 15

<210> 5  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> peptide

<400> 5  
Asn Thr Thr Tyr Leu Trp Trp Val Asn Gly Gln Ser Leu Pro Val  
1 5 10 15

<210> 6  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> peptide

<400> 6  
Tyr Val Cys Gly Ile Gln Asn Ser Val Ser Ala Asn Arg Ser Asp  
1 5 10 15

<210> 7  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> peptide

<400> 7  
Ser Ala Ser Asn Pro Ser Pro Gln Tyr Ser Trp Arg Ile Asn Gly  
1 5 10 15

<210> 8  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> peptide

<400> 8  
Val Ile Leu Asn Val Leu Tyr Gly Pro Asp Ala Pro Thr Ile Ser  
1 5 10 15

<210> 9  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> peptide

<400> 9  
Gly Pro Tyr Glu Cys Gly Ile Gln Asn Glu Leu Ser Val Asp His  
1 5 10 15

<210> 10  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> peptide

<400> 10  
Ser Pro Ser Tyr Thr Tyr Tyr Arg Pro Gly Val Asn Leu Ser Leu  
1 5 10 15

<210> 11  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> peptide

<400> 11  
Pro Ser Pro Gln Tyr Ser Trp Arg Ile Asn Gly Ile Pro Gln Gln  
1 5 10 15

<210> 12  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> peptide

<400> 12  
Asn Asn Ser Ile Val Lys Ser Ile Thr Val Ser Ala Ser Gly Thr  
1 5 10 15

<210> 13  
<211> 9  
<212> DNA

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Kozak sequence

<400> 13  
gccgccacc

9

<210> 14  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> T-cell epitope

<400> 14  
Cys Gly Ile Gln Asn Ser Val Ser Ala  
1 5

<210> 15  
<211> 2034  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> hCEA-ΔAD

<400> 15  
atggagagacc ccagcgcccc cccccaccgc tgggtgcatcc cctggcagcg cctgctgctg 60  
accgccagcc tgcctgacctt ctggaacccc cccaccaccg ccaagctgac catcgagagc 120  
accccccttca acgtggccga gggcaaggag gtgctgctgc tgggtgcacaa cctgccccag 180  
cacctgttctg gctacagctg gtacaagggc gagcgctgag acggcaaccg ccagatcatc 240  
ggctacgtga tcggcaccga gcaggccacc cccggccccg cctacagcgg ccgcgagatc 300  
atctacccca acgccagcct gctgatccag aacatcatcc agaacgacac cggcttctac 360  
accctgcacg tgatcaagag cgacctggtg aacgaggagg ccaccggcca gttccgcgtg 420  
taccgccagc tgcccaagcc cagcatcagc agcaacaaca gcaagcccggt ggaggacaag 480  
gacgccgtgg ccttcacctg cgagccccgag acccaggacg ccacctacct gtgggtgggtg 540  
aacaaccaga gcctgcccgt gagcccccg cctgcagctga gcaacggcaa ccgcaccctg 600  
accctgttca acgtgacccg caacgacacc gccagctaca agtgcgagac ccagaacccc 660  
gtgagcgccc gccgcagcga cagcgtgatc ctgaacgtgc tgtacggccc cgacgcccc 720  
accatcagcc ccctgaacac cagctaccgc agcggcgaga acctgaacct gagctgccac 780  
gccgccagca acccccccg ccagtacagc tggttcgtga acggcacctt ccagcagagc 840  
accaggagc tgttcatccc caacatcacc gtgaacaaca gcggcagcta cacctgccag 900  
gcccaaca gcgacaccgg cctgaaccgc accaccgtga ccaccatcac cgtgtacgcc 960  
gagccccca agcccttcat caccagcaac aacagcaacc ccgtggagga cgaggacgcc 1020  
gtggccctga cctgcgagcc cgagatccag aacaccacct acctgtggtg ggtgaacaac 1080  
cagagcctgc ccgtgagccc ccgcctgcag ctgagcaacg acaaccgcac cctgaccctg 1140  
ctgagcgtga cccgcaacga cgtgggcccc tacgagtgcg gcatccagaa cgagctgagc 1200  
gtggaccaca gcgaccccgat gatcctgaac gtgctgtacg gccccgacga cccaccatc 1260  
agccccagct acacctacta ccgccccggc gtgaacctga gcctgagctg ccacgcgcc 1320  
agcaaccccc ccgcccagta cagctggctg atcgacggca acatccagca gcacaccag 1380  
gagctgttca tcagcaacat caccgagaag aacagcggcc tgtacacctg ccaggccaac 1440

```

aacagcgcca gcgccacag cgcaccacc gtgaagacca tcaccgtgag cgccgagctg 1500
cccaagccca gcatcagcag caacaacagc aagcccgtgg aggacaagga cgccgtggcc 1560
ttcacctgcg agcccgaggc ccagaacacc acctacctgt ggtgggtgaa cgccagagc 1620
ctgcccgtga gccccgcct gcagctgagc aacggcaacc gcaccctgac cctgttcaac 1680
gtgaccgca acgacgccc cgcctacgtg tgcggcatcc agaacagcgt gagcgccaac 1740
cgcagcgacc ccgtgaccct ggacgtgctg tacggccccg acacccccat catcagcccc 1800
cccagacgca gctacctgag cggcgccaac ctgaacctga gctgccacag cgccagcaac 1860
cccagcccc agtacagctg gcgcatcaac ggcaccccc agcagcacac ccagggtgctg 1920
ttcatcgcca agatcacccc caacaacaac ggcacctacg cctgcttcgt gagcaacctg 1980
gccaccggcc gcaacaacag catcgtgaag agcatcacgc tgagcgccag cggc      2034

```

&lt;210&gt; 16

&lt;211&gt; 678

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; hCEA-ΔAD

&lt;400&gt; 16

```

Met Glu Ser Pro Ser Ala Pro Pro His Arg Trp Cys Ile Pro Trp Gln
 1           5           10           15
Arg Leu Leu Leu Thr Ala Ser Leu Leu Thr Phe Trp Asn Pro Pro Thr
      20           25           30
Thr Ala Lys Leu Thr Ile Glu Ser Thr Pro Phe Asn Val Ala Glu Gly
      35           40           45
Lys Glu Val Leu Leu Leu Val His Asn Leu Pro Gln His Leu Phe Gly
 50           55           60
Tyr Ser Trp Tyr Lys Gly Glu Arg Val Asp Gly Asn Arg Gln Ile Ile
 65           70           75           80
Gly Tyr Val Ile Gly Thr Gln Gln Ala Thr Pro Gly Pro Ala Tyr Ser
      85           90           95
Gly Arg Glu Ile Ile Tyr Pro Asn Ala Ser Leu Leu Ile Gln Asn Ile
      100          105          110
Ile Gln Asn Asp Thr Gly Phe Tyr Thr Leu His Val Ile Lys Ser Asp
      115          120          125
Leu Val Asn Glu Glu Ala Thr Gly Gln Phe Arg Val Tyr Pro Glu Leu
      130          135          140
Pro Lys Pro Ser Ile Ser Ser Asn Asn Ser Lys Pro Val Glu Asp Lys
 145          150          155          160
Asp Ala Val Ala Phe Thr Cys Glu Pro Glu Thr Gln Asp Ala Thr Tyr
      165          170          175
Leu Trp Trp Val Asn Asn Gln Ser Leu Pro Val Ser Pro Arg Leu Gln
      180          185          190
Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Phe Asn Val Thr Arg Asn
      195          200          205
Asp Thr Ala Ser Tyr Lys Cys Glu Thr Gln Asn Pro Val Ser Ala Arg
 210          215          220
Arg Ser Asp Ser Val Ile Leu Asn Val Leu Tyr Gly Pro Asp Ala Pro
 225          230          235          240
Thr Ile Ser Pro Leu Asn Thr Ser Tyr Arg Ser Gly Glu Asn Leu Asn
      245          250          255
Leu Ser Cys His Ala Ala Ser Asn Pro Pro Ala Gln Tyr Ser Trp Phe
      260          265          270
Val Asn Gly Thr Phe Gln Gln Ser Thr Gln Glu Leu Phe Ile Pro Asn

```

```

Ile Thr Val Asn Asn Ser Gly Ser Tyr Thr Cys Gln Ala His Asn Ser
 290                295                300
Asp Thr Gly Leu Asn Arg Thr Thr Val Thr Thr Ile Thr Val Tyr Ala
305                310                315                320
Glu Pro Pro Lys Pro Phe Ile Thr Ser Asn Asn Ser Asn Pro Val Glu
                325                330                335
Asp Glu Asp Ala Val Ala Leu Thr Cys Glu Pro Glu Ile Gln Asn Thr
                340                345                350
Thr Tyr Leu Trp Trp Val Asn Asn Gln Ser Leu Pro Val Ser Pro Arg
                355                360                365
Leu Gln Leu Ser Asn Asp Asn Arg Thr Leu Thr Leu Leu Ser Val Thr
                370                375                380
Arg Asn Asp Val Gly Pro Tyr Glu Cys Gly Ile Gln Asn Glu Leu Ser
385                390                395                400
Val Asp His Ser Asp Pro Val Ile Leu Asn Val Leu Tyr Gly Pro Asp
                405                410                415
Asp Pro Thr Ile Ser Pro Ser Tyr Thr Tyr Tyr Arg Pro Gly Val Asn
                420                425                430
Leu Ser Leu Ser Cys His Ala Ala Ser Asn Pro Pro Ala Gln Tyr Ser
                435                440                445
Trp Leu Ile Asp Gly Asn Ile Gln Gln His Thr Gln Glu Leu Phe Ile
450                455                460
Ser Asn Ile Thr Glu Lys Asn Ser Gly Leu Tyr Thr Cys Gln Ala Asn
465                470                475                480
Asn Ser Ala Ser Gly His Ser Arg Thr Thr Val Lys Thr Ile Thr Val
                485                490                495
Ser Ala Glu Leu Pro Lys Pro Ser Ile Ser Ser Asn Asn Ser Lys Pro
                500                505                510
Val Glu Asp Lys Asp Ala Val Ala Phe Thr Cys Glu Pro Glu Ala Gln
                515                520                525
Asn Thr Thr Tyr Leu Trp Trp Val Asn Gly Gln Ser Leu Pro Val Ser
530                535                540
Pro Arg Leu Gln Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Phe Asn
545                550                555                560
Val Thr Arg Asn Asp Ala Arg Ala Tyr Val Cys Gly Ile Gln Asn Ser
                565                570                575
Val Ser Ala Asn Arg Ser Asp Pro Val Thr Leu Asp Val Leu Tyr Gly
                580                585                590
Pro Asp Thr Pro Ile Ile Ser Pro Pro Asp Ser Ser Tyr Leu Ser Gly
                595                600                605
Ala Asn Leu Asn Leu Ser Cys His Ser Ala Ser Asn Pro Ser Pro Gln
610                615                620
Tyr Ser Trp Arg Ile Asn Gly Ile Pro Gln Gln His Thr Gln Val Leu
625                630                635                640
Phe Ile Ala Lys Ile Thr Pro Asn Asn Asn Gly Thr Tyr Ala Cys Phe
                645                650                655
Val Ser Asn Leu Ala Thr Gly Arg Asn Asn Ser Ile Val Lys Ser Ile
                660                665                670
Thr Val Ser Ala Ser Gly
                675

```



(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
18 November 2004 (18.11.2004)

PCT

(10) International Publication Number  
WO 2004/099247 A3

(51) International Patent Classification<sup>7</sup>: C07K 14/705,  
C12N 15/85, 15/861, A61P 35/00, A61K 39/00

(74) Agent: BUCHAN, Gavin, MacNicol; Terlings Park, East-  
wick Road, Harlow, Essex CM20 2QR (GB).

(21) International Application Number:  
PCT/EP2004/004802

(22) International Filing Date: 3 May 2004 (03.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/467,971 5 May 2003 (05.05.2003) US  
60/543,612 11 February 2004 (11.02.2004) US

(71) Applicant (for all designated States except US): ISTI-  
TUTO DI RICERCHE DI BIOLOGIA MOLECO-  
LARE P ANGELETTI SPA [IT/IT]; Via Pontina KM  
30.600, I-00040 Pomezia, Rome (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LA MONICA,  
Nicola [IT/IT]; IRBM, Via Pontina KM 30.600, I-00040  
Pomezia, Rome (IT). LAHM, Armin [DE/IT]; IRBM,  
Via Pontina KM 30.600, I-00040 Pomezia, Rome (IT).  
MENNUNI, Carmela [IT/IT]; IRBM, Via Pontina KM  
30.600, I-00040 Pomezia, Rome (IT). SAVINO, Rocco  
[IT/IT]; IRBM, Via Pontina KM 30.600, I-00040 Pomezia,  
Rome (IT).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
24 February 2005

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: SYNTHETIC GENE ENCODING HUMAN CARCINOEMBRYONIC ANTIGEN AND USES THEREOF

(57) Abstract: Synthetic polynucleotides encoding human carcinoembryonic antigen (CEA) are provided, the synthetic polynucleotides being codon-optimized for expression in a human cellular environment. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying codon-optimized human CEA and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

WO 2004/099247 A3

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/004802

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/705 C12N15/85 C12N15/861 A61P35/00 A61K39/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07K A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, EMBASE, FSTA, Sequence Search, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BERINSTEIN NEIL L: "Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review." JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. 15 APR 2002, vol. 20, no. 8, 15 April 2002 (2002-04-15), pages 2197-2207, XP008037964 ISSN: 0732-183X the whole document ----- -/--	1-28

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*A\* document member of the same patent family

Date of the actual completion of the international search

10 November 2004

Date of mailing of the international search report

26/11/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Piret, B

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/004802

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCHOLL SUSY M ET AL: "Gene therapy applications to cancer treatment." JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, vol. 2003, no. 1, 19 March 2003 (2003-03-19), pages 35-47, XP002304653 ISSN: 1110-7243 the whole document	1-28
A	WO 02/38769 A (DEUTSCHES KREBSFORSCH ; IPK INST FUER PFLANZENGENETIK (DE); SONNEWALD) 16 May 2002 (2002-05-16)	

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2004/004802

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8-13, 19-24  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 8 (partially), 9-13 and 19-24 are directed to methods of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/004802

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0238769 A	16-05-2002	DE 10055545 A1	25-07-2002
		AU 1380602 A	21-05-2002
		WO 0238769 A2	16-05-2002
<hr/>			

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**